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also	 representing	 different	 aspects	 of	 our	 field	 from	 CNS	 applications	 to	 therapeutic	 radio-
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many	 international	airlines	and	 low-cost	 carriers.	Direct	 flights	 to	Salzburg	are	available	 from	



























The	 power	 supply	 in	 Austria	 is	 220/240	 Volt-current.	 Most	 electric	 outlets	 adhere	 to	 the	
continental	standard	(Schuko).	Appliances	from	North	America	require	a	transformer	and	British	
appliances	require	an	adaptor	for	the	two-pin	sockets	in	use	in	Austria.	
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farmers.	 Even	 the	 simpler	 restaurants	 serve	 fine	 delicacies	 from	 the	 Salzburg	 region.Four	
extraordinary	breweries	in	the	city	of	Salzburg	invite	guests	to	enjoy	a	hearty	snack	in	a	convivial	
atmosphere.	Favorite	places	to	grab	a	bite	in	between	are	the	delicatessen	shops	in	Salzburg's	
























reduced	 rate	 of	 10%.	 Most	 services	 do	 not	 include	 tipping.	 In	 higher	 class	 restaurants	 it	 is	
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12:45	 	 	 Farewell	Lunch	
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19:40	 OP01		 Welcome	Lecture	 C.	Decristoforo,	Austria	
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08:30	 OP02	 The	isotope	revolution	that	can	change	imaging	and	therapy	 M.	Jensen,	Denmark	
09:15	 OP03	 Selective	Extraction	of	Medically-Related	Radionuclides	from	Proton-	
	 	 Irradiated	Thorium	Targets	 V.	Radchenko,	USA	
09:27	 OP04	 Comparison	of	[68Ga]FSC(succ-RGD)3	and	[68Ga]NODAGA-RGD	for		
	 	 PET	imaging	of	αvβ3	integrin	expression	 C.	Zhai,	Austria	
09:39	 OP05	 A	new	NPY-Y1R	targeting	peptide	for	breast	cancer	PET	imaging	 B.	Guérin,	Canada	
09:51	 OP06	 The	influence	of	multivalency	on	CCK	2	receptor	targeting	 D.	Summer,	Austria	
10:03	 OP07	 SPECT	Imaging	of	αvβ3	Expression	by	[99mTc(N)PNP43]-		





10:45	 OP08	 Speed	matters!	Shortening	time	from	EOB	to	product	release	 W.	Wadsak,	Austria	
11:30	 OP09	 New	dienophiles	for	the	inverse-electron-demand	Diels-Alder		
	 	 reaction	and	for	pretargeted	PET	imaging.	 E.	Billaud,	Belgium	
11:42	 OP10	 New	complexing	agent	for	Al18F-labelling	of	heat-sensitive	biomolecules:	
	 	 Synthesis	and	preclinical	evaluation	of	Al18F-RESCA1-HSA	 F.	Cleeren,	Belgium	
11:54	 OP11	 A	novel	versatile	precursor	efficient	for	F-18	radiolabelling	via	click-chemistry	 B.	Lugatoa,	Italy	
12:06	 OP12	 A	general	applicable	method	to	quantify	unidentified	UV	impurities	
	 	 in	radiopharmaceuticals	 R.	Klok,	The	Netherlands	
12:18	 OP13	 Development	of	[18F]Fluoro-C-glycosides	to	radiolabel	peptides		
	 	 for	PET	application	 C.	Collet,	France	
12:30	 OP14	 A	Microfluidic	Approach	for	the	68Ga-labeling	of		






	 	 A	radiobiology	perspective	 J-P.	Pouget,	France	
15:00	 OP16	 Surprising	reactivity	of	astatine	in	the	nucleophilic	substitution		
	 	 of	aryliodonium	salts:	application	to	the	radiolabeling	of	antibodies	 F.	Guérard,	France	
15:12	 OP17	 64Cu-NOTA-pertuzumab	F(ab')2	fragments,	a	second-generation	probe		
	 	 for	PET	imaging	of	the	response	of	HER2-positive	breast	cancer	to		
	 	 trastuzumab	(Herceptin)	 K.	Lam,	Canada	
15:24	 OP18	 Development	of	radiohalogenated	analogues	of	a	avb6-specific	peptide		
	 	 for	high	LET	particle	emitter	targeted	radionuclide	therapy	of	cancer.	 S.	Paillas,	UK	





17:00	 OP20	 Good	or	bad?	Why	ethics	in	animal	studies	matter?	 S.	Heskamp,	The	Netherlands	
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	 	 Their	design	for	diagnosis	and	therapy	of	prostate	cancer	 K.	Kopka,	Germany	
09:15	 OP23	 The	radiosynthesis	of	an	18F-labeled	triglyceride,	developed		
	 	 to	visualize	and	quantify	brown	adipose	tissue	activity	 M.	Bauwens,	The	Netherlands	
09:27	 OP24	 Influence	of	the	fluorescent	dye	on	the	tumor	targeting		
	 	 properties	of	dual-labeled	HBED-CC	based	PSMA	inhibitors	 A-C.	Baranski,	Germany	
09:39	 OP25	 [18F]MEL050	as	a	melanin	PET	tracer	:	fully	automated	
	 	 radiosynthesis	and	evaluation	for	the	detection	of	pigmented		
	 	 melanoma	in	mice	pulmonary	metastases	 N.	Rizzo-Padoin,	France	
09:51	 OP26	 Design	and	Preclinical	Evaluation	of	Novel	Radiofluorinated		
	 	 PSMA	Targeting	Ligands	Based	on	PSMA-617	 J.	Cardinale,	Germany	
10:03	 OP27	 A	Novel	Radiolabeled	Peptide	for	PET		





10:45	 OP28	 	Molecular	future	in	psychiatry	 R.	Lanzenberger,	Austria	
11:30	 OP29	 Biodistribution	of	[18F]Amylovis®,	a	new	radiotracer		
	 	 PET	imaging	of	β-amyloid	plaques	 L.	Fernández	Maza,	Spain	
11:42	 OP30	 Synthesis	and	preclinical	evaluation	of	[11C]-BA1	PET		
	 	 tracer	for	the	imaging	of	CSF-1R	 B:	Attili,	Belgium	
11:54	 OP31	 In	vivo	imaging	of	the	MCHR1	in	the	ventricular	system	via	[18F]FE@SNAP	 C.	Philippe,	Austria	
12:06	 OP32	 Synthesis	of	the	first	carbon-11	labelled	P2Y12	receptor	antagonist	for		
	 	 imaging	the	anti-inflammatory	phenotype	of	activated	microglia	 B.	Janssen,	The	Netherlands	
12:18	 OP33	 Radiosynthesis	of	a	selective	HDAC6	inhibitor		
	 	 [11C]KB631	and	in	vitro	and	ex	vivo	evaluation.	 K.	Vermeulen,	Belgium	
12:30	 OP34	 Improving	metabolic	stability	of	fluorine-18	labelled		








14:15	 OP35	 What	you	see	is	not	what	you	should	treat:	Image	artifacts	–	The	don´ts	 T.	Beyer,	Germany	
15:00	 OP36	 Development	of	a	novel	PET	tracer	for	the	
	 	 activin	receptor-like	kinase	5	 L.	Rotteveel,	The	Netherlands	
15:12	 OP37	 SPECT	Imaging	and	Biodistribution	Studies	of	111In-EGF-Au-PEG	Nanoparticles	In	Vivo	 L.	Song,	UK	
15:24	 OP38	 Melanoma	targeting	with	[99mTc(N)(PNP3)]-labeled		
	 	 NAPamide	derivatives:	preliminary	pharmacological	studies	 C.	Bolzati,	Italy	





16:30	 OP40	 How	to	use	the	Eur.	Pharmacopoeia	and	how	to	contribute	 E.	Pel,	France	
16:40	 OP41	 New	monographs	and	chapters	in	the	Eur.	Pharmacopoeia	 T.	Kroon,	The	Netherlands	
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08:30	 OP42	 Validation	&	Qualification:	a	GMP	burden	or	an	opportunity?	 S.	Todde,	Italy	
09:00	 OP43	 Validation	Quiz	 A.	Gee,	UK	&	P.	Kolenc	Peitl,	Slovenia	
09.40	 OP44	 Implementation	of	a	GMP-grade	radiopharmacy	facility	in	Maastricht	 M.	Bauwens,	The	Netherlands	
09.52	 OP45	 Setting	up	a	GMP	production	of	a	new	radiopharmaceutical	 S.	Forsback,	Finland	





11:00	 OP47	 Why	are	investors	not	interested	in	my	radiotracers?	 R.	Zimmermann,	France	
11:45	 OP48	 In	Vitro	and	In	Vivo	Evaluation	of	68-Gallium	Labeled	Fe3O4-DPD		
	 	 Nanoparticles	as	Potential	PET/MRI	Imaging	Agents.	 M.	Karageorgou,	Greece	
11:57	 OP49	 Fast	PET	imaging	of	inflammation	using	68Ga-citrate	with		
	 	 Fe-containing	salts	of	hydroxy	acids	 A.S.	Lunev,	Russia	
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the	 US	 FDA	 approval	 of	 several	 radionuclide	 based	 drugs	 [3].	 Combinations	 of	 several	 types	 of	
radionuclide	emissions	for	therapy	(i.e.,	α-therapeutic	agent	combined	with	β-	therapeutic)	could	lead	to	
even	more	effective	treatment	options	[4].	One	of	the	limiting	factors	in	the	development	of	TR	as	a	widely	
adopted	 treatment	option	 is	 the	availability	of	 select	 radionuclides	with	optimum	emission	properties	
(both	 in	 volume	 and	 periodicity	 of	 delivery),	 which	 poses	 a	 challenge	 due	 to	 the	 fact	 that	 different	
radionuclides	 typically	 require	 different	 target	 materials	 and/or	 nuclear	 reaction	 pathways	 for	 their	
formation.	Materials	&	Methods:	We	already	published	a	successful	strategy	for	the	isolation	of	225/227Ac	
from	 irradiated	 thorium	 targets	 [5].	 We	 also	 published	 the	 recovery	 of	 Pa	 isotopes	 [6]	 from	 proton	
irradiated	thorium.	In	this	work,	we	propose	the	isolation	of	several	other	medically	related	radionuclides	
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the	 integrin	 αvβ3	 receptor	 that	 plays	 an	 important	 role	 in	 tumor	 angiogenesis.	 Recently	we	 reported	
[68Ga]FSC(succ-RGD)3,	a	trimeric	RGD	peptide,	exhibited	excellent	targeting	properties	for	αvβ3	 integrin	
expression	and	significant	improved	tumor	uptake	compared	to	monomeric	[68Ga]NODAGA-RGD.(1)	Here	
we	report	the	PET	 imaging	properties	of	 [68Ga]FSC(succ-RGD)3	 in	different	xenograft	 tumor	model	and	
compared	 them	 with	 [68Ga]NODAGA-RGD.	 Materials	 &	 Methods:	 The	 PET	 imaging	 properties	 of	
[68Ga]FSC(succ-RGD)3	were	studied	in	nude	mice	bearing	M21	human	melanoma	xenografts	and	human	
glioblastoma	 U87MG	 xenograft	 tumor.	 A	 parallel	 PET	 imaging	 of	 68GaNODAGA-RGD	 	 in	 same	mouse	
bearing	 	 U87MG	 xenograft	 tumor	 was	 performed	 as	 a	 comparison.	Results	 :The	 static	 PET	 image	 of	
[68Ga]FSC(succ-RGD)3	 in	 nude	 mice	 showed	 highly	 visualized	 tumors	 of	 M21	 (positive)	 whereas	
nonvisualized	tumor	of	M21-L	(negative)	tumor	xenografts	1	h	post	injection	confirming	receptor-specific	
activity	 accumulation.	 The	 dynamic	 PET	 images	 of	 [68Ga]FSC(succ-RGD)3	 showed	 rapid	 clearance	 of	
[68Ga]FSC(succ-RGD)3	from	the	circulation	while	the	tumor	remained	clearly	visible.	A	direct	comparison	







contrast	using	 less	radioactivity	as	well	as	detect	 low-level	 integrin	expression.	Discussion/Conclusion:	
[68Ga]FSC(succ-RGD)3	shows	the	advantages	in	the	respect	of	delayed	imaging,	reduced	radiation	dose	as	
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Background:	 Multivalency	 has	 shown	 to	 enhance	 accumulation	 of	 receptor	 targeted	
radiopharmaceuticals,	 due	 to	 the	 avidity	 effect	 and	 increased	 apparent	 tracer	 concentration.	 For	
metabolically	unstable	peptides	multimerisation	may	also	delay	metabolic	processes	like	oxidation	and	
enzymatic	cleavage	leading	to	loss	of	binding	affinity.	The	aim	of	this	study	was	to	show	the	benefit	of	














tumour	 uptake	 ranging	 from	 5%	 (monomer)	 to	 approximately	 10%	 ID/g	 (multimer)	 one	 hour	 post	
injection.	Tumour	to	organ	ratio	was	decreased	by	multimerisation	and	especially	the	kidney	retention	
was	increased	significantly	by	the	di-	and	trimeric	radiotracers.	Static	animal	imaging	one	and	two	hours	
after	 injection	of	68Ga	 labeled	conjugates	confirmed	 the	outcome	of	 the	biodistribution	studies.	89Zr	
labeled	 counterparts	 showed	 very	 similar	 results	 but	 after	 24	 hours	 post	 injection	 the	 trimeric	
bioconjugate	 showed	much	 better	 tumour	 imaging	 ability	 than	 the	 corresponding	mono-	 and	 dimer.	
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Asp	 pentapeptide	 covalently	 bound	 to	 an	 echistatin	 domain,	 has	 been	 reported1.	 In	 vitro	 and	 in	 vivo	
biological	studies	evidenced	that	this	chimeric	peptide	selectively	binds	to	αvβ3	 integrin	and	does	not	
cross-react	with	αvβ52.	In	order	to	obtain	an	optimal	SPECT	radiotracer,	a	series	of	[99mTc(N)PNP]	labelled	
peptides	 has	 been	 prepared	 and	 their	 pharmacological	 properties	 investigate.	Materials	 &	Methods:	
RGDechi-hCit	 	 (1)	 and	 three	 truncated	 peptide	 derivatives	 [RGDechi1_17	 (2),	 RGDechi1_16	 (3)	 and	
RGDechi1_14	(4)]	lacking	the	two,	three	and	five	C-terminal	amino	acids,	were	synthetized	in	solid	phase	
by	Fmoc	chemistry	and	conjugated	with	a	cysteine	linked	to	the	Lys1	side	chain	to	allow	the	labeling	with	
[99mTc(N)PNP43]-synthon	 (PNP43	 =	 (CH3)2P(CH2)2N(C2H4OCH3)(CH2)2P(CH3)2).	 In	 vitro	 stability	 and	
pharmacological	parameters	of	the	corresponding	compounds,	99mTc1-4,	were	assessed.	Challenges	with	
an	excess	of	glutathione	and	cysteine	and	Log	P	values	were	also	investigated.	Furthermore,	radiolabeled	






uptake	 assays	 showed	 that,	 excluding	 99mTc4	 compound,	 99mTc1-3	 radiolabeled	 peptides	 accumulate	
selectively	in	cells	expressing	αvβ3	integrin	and	does	not	accumulate	in	cell	expressing	moderate	levels	of	
αvβ5	and	undetectable	levels	of	αvβ3	integrins.	In	agreement	with	in	vitro	findings,	biodistribution	studies	
showed	 that	 the	 99mTc1-3	 radiolabeled	 chimeric	 peptide	 selectively	 localizes	 in	 tumor	 xenografts	
expressing	αvβ3	and	fails	to	accumulate	in	those	expressing	αvβ5	integrin.	Discussion/Conclusion:	99mTc-
labeled	 RGDechi,	 RGDechi1_17	 and	 RGDechi1_16	 chimeric	 peptides	 can	 be	 used	 for	 highly	 selective	
αvβ3	expression	 imaging	by	SPECT	 technology.	Among	 the	 tested	compounds,	 99mTc2	possess	 the	best	
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New	 dienophiles	 for	 the	 inverse-electron-demand	 Diels-Alder	 reaction	 and	 for	 pretargeted	 PET	
imaging.	
Emilie	 Billaud1,	 Muneer	 Ahamed1,	 Frederik	 Cleeren1,	 Elnaz	 Shahbazali2,	 Tim	 Noël2,	 Volker	 Hessel2,	
Alfons	Verbruggen1	and	Guy	Bormans1	
1	Laboratory	of	Radiopharmacy,	KU	Leuven,	Leuven,	Belgium	
2	Micro	 Flow	 Chemistry	&	 Process	 Technology,	 Chemical	 Engineering	 and	 Chemistry	 Department,	 TU	
Eindhoven,	The	Netherlands	
	




antibodies	 with	 the	 rapid	
pharmacokinetics	 and	 favorable	
dosimetry	 of	 smaller	 molecule	
radiolabeled	 with	 short-lived	
radionuclides.	 This	 approach	 can	 be	
based	 on	 the	 bioorthogonal	 inverse-
electron-demand	 Diels-Alder	 (IEDDA)	
“click”	 reaction	 between	 tetrazines	
and	 trans-cyclooctene	 (TCO)	
derivatives.	 Our	 project	 aims	 to	 develop	 new	 [18F]TCO-dienophiles	with	 high	 reactivity	 for	 the	 IEDDA	
reaction,	improved	in	vivo	stability	and	favorable	pharmacokinetics.	New	dienophiles			were			synthesized			
using	 an	 innovative	 continuous-flow	micro-photochemistry	 process,	 and	 their	 reaction	 kinetics	with	 a	
tetrazine	were	determined.	In	vivo	stability	studies	of	the	most	promising	18F-radiolabeled-TCO-derivative	
([18F]trans-EB-70)	was	investigated,	and	its	potential	for	pretargeted	PET	imaging	was	assessed.Materials	










slices	 (LNCaP	 and	 PC-3	 cells)	were	 successively	 incubated	with	 a	 prostate-specific	membrane	 antigen	
(PSMA)	 inhibitor	modified	with	3-(4-(trifluoromethyl)phenyl)-6-phenyl-1,2,4,5-tetrazine,	and	 [18F]trans-
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binding	was	 observed	 in	 PC-3	 cells	 (negative	 control).	Discussion/Conclusion:	We	 demonstrated	 that	
[18F]trans-EB-70	is	a	suitable	dienophile	for	the	IEDDA	“click”	reaction	and	for	pretargeting	applications.	
Therefore,	 [18F]trans-EB-70	 will	 be	 investigated	 further	 in	 pretargeted	 µPET	 experiments.	 Research	
support:	SBO	MIRIAD	(IWT	Flanders)	
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Introduction:	 The	 Al18F-labelling	 strategy	 involves	 formation	 of	 aluminium	 mono[18F]fluoride	
({Al18F}2+)	 which	 is	 trapped	 by	 a	 suitable	 chelator	 –mostly	 bound	 to	 a	 biomolecule-	 in	 aqueous	
medium.1At	this	moment	however,	the	need	for	elevated	temperatures	(100-120	°C)	limits	its	widespread	
use.	 Therefore,	 we	 designed	 new	 restrained	 complexing	 agents	 (RESCAs)	 for	 use	 of	 this	 strategy	 at	
moderate	temperature.	RESCA1	 is	an	acyclic	pentadentate	 ligand	with	a	N2O3	coordinative	set	that	 is	
able	to	complex	{Al18F}2+		efficiently	at	25	°C.	To	evaluate	the	stability	and	kinetic	inertness	of	the	chelate	
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and	azides	emerged	as	a	powerful	 tool	 in	F-18	 labelling	biomolecules	such	as	peptides,	because	of	 its	




Aldrich.	 [18F]Fluoride	 was	 produced	 with	 an	 IBA	 Cyclone	 18/9	 cyclotron.	 Radioactive	 syntheses	 were	
carried	 out	 on	 a	 fully	 automated	 radiosynthesis	 module	 (GE	 TracerLab	 FX-FN	 Pro),	 and	 analyzed	 by	
analytical	 RP-HPLC	 with	 UV	 and	 radiochemical	 detectors.	 Non-radioactive	 compounds	 were	 fully	









radiochemical	 purity.	 The	 purified	 azide	 was	 then	 conjugated	 to	 propargylglycine,	 showing	 52%	
conversion	within	30	min	at	room	temperature.	Purification	and	formulation	have	still	to	be	optimized.	
Discussion/Conclusion:	A	new	optimized	precursor	useful	for	F-18	radiolabelling	and	click-chemistry	was	
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Introduction:	 Radiopharmaceuticals	 are	 released	 for	 administration	 by	 a	 quality	 control	 procedure	
against	 pre-set	 specifications.	 One	 of	 these	 release	 specifications	 is	 the	 chemical	 purity	 of	 the	 drug	
product,	 determined	 with	 High	 Pressure	 Liquid	 Chromatography	 (HPLC)	 and	 UV	 detection.	 In	 the	
European	 Pharmacopeia	 (EP)	 hardly	 any	 specifications	 are	 given	 for	 the	 chemical	 purity	 of	 a	
radiopharmaceutical.	When	unknown	 impurities	are	present	 in	 the	 chromatogram,	 the	decision	 if	 the	
radiopharmaceutical	can	be	released,	is	very	frequently	based	on	unclear	parameters	like	‘no	unidentified	
UV	signals	present’.	There	 is	a	need	for	an	objective	specification	 in	order	 to	have	a	save	and	reliable	
release.	Aim:	The	purpose	of	 the	presented	work	 is	 to	define	a	generally	applicable	method	to	define	
tolerances	 for	 unidentified	 impurities	 in	 radiopharmaceuticals.	Materials	&	Methods:	A	 retrospective	
analysis	 was	 performed	 on	 HPLC	 analysis	 results	 of	 [11C]Flumazenil,	 [11C]PIB,	 [11C]Erlotinib,	
[11C]DPA713,	[18F]PK209	and	[18F]FES.	Quantification	of	the	carrier	signal	in	the	UV	chromatogram	was	
determined	by	use	of	calibration	curves,	utilizing	Chromeleon®	6.8.	Unidentified	impurities	were	semi-
quantified	 utilizing	 the	 surface	 area	 in	 the	UV	 chromatogram	 relative	 to	 the	 quantified	 carrier	 signal.	
Based	 on	 the	 EP.	monography	 of	 [11C]Flumazenil	 and	 [18F]FET,	 the	 specification	 for	 unidentified	UV	
impurities	was	determined	to	be	0.22	pmol/injection	volume	for	a	single	unidentified	impurity	and	0.88	
pmol/injection	volume	for	the	total	of	unidentified	impurities.	This	specification	was	tested	for	over	500	
batches	of	 the	radiopharmaceuticals	and	compared	to	the	 less	specific	parameter	 ‘no	unidentified	UV	
signals	present’.	Results:	In	a	pilot	assessment	we	encountered	in	5-10%	cases	unidentified	UV	impurities	
leading	to	rejection	of	the	batch,	based	on	the	specification	‘no	unidentified	UV	signals	present’.	Of	these	
rejected	 batches	 25%	was	 also	 rejected	with	 the	 new	 defined	 specification.	 Reason	 for	 this	 reduced	
number	 of	 rejections	 is	 that	 with	 the	 new	 specification	 the	 presence	 of	 unidentified	 impurities	 is	
evaluated	objectively.	The	analysis	of	the	full	database	is	currently	on-going.	Discussion/Conclusion:	With	
this	method	the	amount	of	unidentified	 impurities	can	be	estimated	 in	an	optimal	and	objective	way,	
utilizing	EP	 limits	of	 [11C]Flumazenil	 and	 [18F]FET,	without	operator	 variability.	References:	 European	
Pharmacopeia	8.0-8.6.	
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few	 recent	 examples.	 A	 solution	 is	 to	 use	 a	 prosthetic	 group,	 an	 easily	 radiolabeled	 small	 molecule,	
subsequently	 coupled	 in	 mild	 condition	 to	 the	 peptide.	 In	 continuation	 of	 our	 previous	 work,2	 we	
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proof-of-principle	 study,	 the	 68Ga-radiolabeling	 of	 PSMAHBED-CC	 and	 NODAGA-RGD	 using	 a	 microfluidic	
approach	was	evaluated.	Furthermore,	adding	TWEEN	20	(a	surfactant	suitable	for	in	vivo	applications)	
and	its	impact	on	the	radiochemical	yield	was	explored.	Materials	and	Methods:	The	syntheses	of	68Ga-
PSMAHBED-CC	 and	 68Ga-NODAGA-RGD	 (both	 precursors	 from	 ABX)	 were	 performed	 using	 an	 Advion	
NanoTek	LF	microfluidic	device.	The	system	incorporates	a	flow-through	reactor	that	consists	of	a	silica	
capillary	(l=2	m,	Ø100	µm,	V=15.6	µL).	68Ga3+	was	obtained	from	a	68Ge/68Ga-generator	(3.7	GBq;	Obninsk)	
according	 to	 a	 fractionized	 protocol.	 The	 precursor	 and	 68Ga3+	were	 loaded	 in	 two	 storage	 loops	 and	
distinct	volumes	thereof	were	pushed	through	the	reactor	with	different	flowrates	(30,	50,	80	µL/min)	at	
different	 temperatures	 (25,	 50,	 80,	 100,	 120,	 150°C)	 using	 NaOAc	 and	 HEPES	 for	 pH	 adjustment,	
respectively.	Additionally,	the	influence	of	TWEEN	20	as	a	surfactant,	to	reduce	known	adsorption	effects	
in	microfluidic	tubing,	was	investigated.	Results:	Accomplished	experiments	revealed	feasibility	of	68Ga-
labeling	 of	 PSMAHBED-CC	and	NODAGA-RGD	using	 a	microfluidic	 device.	 All	 temperatures	 and	 flowrates	




16.8	%	 (n=13).	Discussion/Conclusion:	This	 study	 provides	 the	 proof-of-principle	 of	 68Ga-labeling	 in	 a	
microfluidic	“flow-through”	system.	The	application	of	TWEEN	20	 led	 to	drastically	 increased	yields	of	
68Ga-PSMAHBED-CC	due	to	 its	surfactant	nature.	As	a	result,	this	microfluidic	approach	will	be	pursued	to	
increase	 availability	 of	 68Ga-radiopharmaceuticals	 according	 to	 the	 dose-on-demand	 principle.	
References:	1	Lee	C,	Sui	G,	Elizarov	A,	Shu	J,	Shin	Y,	Dooley	A,	Huang	J,	Daridon	A,	Wyatt	P,	Stout	D,	Kolb	
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(solvent,	 temperature,	 duration	 and	 counter-ion	 of	 iodonium)	 were	 studied	 on	 model	 compounds.	
Bifunctional	iodonium	salts	were	then	designed,	allowing	the	synthesis	of	[125I]-SIB	and	[211At]-SAB,	two	
prosthetic	groups	widely	used	for	radio-iodination	and	astatination	of	biomolecules.	Both	[125I]-SIB	and	
[211At]-SAB	were	 conjugated	 to	 the	multiple	myeloma	 targeting	mAb	 9E7.4	 (anti-CD138).	 Conjugation	











which	 requires	more	 energy	 for	 the	 reaction	 to	 proceed.	 This	 explains	 the	 large	 reactivity	 difference	





















X = 125I, SIB (RCY = 87%)
X = 211At, SAB (RCY = 93%)
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Introduction:	 SPECT/CT	 imaging	 with	 111In-BzDTPA-pertuzumab	 detected	 trastuzumab	 (Herceptin)-
mediated	HER2	downregulation	in	human	breast	cancer	xenografts	in	mice	and	was	correlated	with	a	good	
response	 to	 treatment.	This	agent	 is	now	being	 studied	 in	a	Phase	 I/II	 clinical	 trial	 sponsored	by	OICR	
(PETRA;	 ClinicalTrials.gov	 identifier:	 NCT01805908).	 Our	 objective	 was	 to	 develop	 and	 characterize	 a	
second-generation	 positron-emitting	 analogue	 for	 PET/CT	 imaging,	 64Cu-NOTA-pertuzumab	 F(ab')2,	 to	
provide	greater	sensitivity,	more	accurate	radiotracer	quantitation	and	a	lower	radiation	absorbed	dose.	
Materials	&	Methods:	 To	 determine	 the	 optimal	 dose,	mice	with	 subcutaneous	 HER2-overexpressing	
tumours	were	injected	with	5,	50,	100	or	200	µg	of	64Cu-NOTA-F(ab')2	(2.2±0.6	MBq)	and	sacrificed	at	24	
h	p.i.	 for	 biodistribution.	 To	determine	 the	normal	 tissue	distribution,	 pharmacokinetics	 and	 radiation	
dosimetry	of	64Cu-NOTA-F(ab')2,	non-tumour	bearing	Balb/c	mice	were	administered	50	µg	of	64Cu-NOTA-
F(ab')2	 (2.9±0.3	 MBq)	 and	 sacrificed	 at	 select	 time	 points.	 Three	 groups	 of	 mice	 bearing	 HER2-




tumour	 to	 blood	 ratio,	 followed	 by	 the	 100,	 5,	 and	 200	 µg	 doses	 (18.2±7.2,	 15.4±0.8,	 14.0±5.0,	 and	




the	 24	 and	 48	 h	 p.i.	 imaging	 time	points.	 Tumour	 accumulation	of	 64Cu-NOTA-F(ab')2	was	 significantly	
higher	in	mice	administered	64Cu-NOTA-F(ab')2	without	pertuzumab	blocking	(8.4±3.4	%ID/g)	relative	to	
mice	pre-injected	with	1	mg	of	pertuzumab	(3.9±0.5	%ID/g;	P	<	0.05),	and	mice	administered	64Cu-NOTA-
F(ab')2	prepared	 from	non-specific	 human	 IgG	 (2.7±0.5	%ID/g;	P	 <	 0.05).	Discussion/Conclusion:	 64Cu-
NOTA-F(ab')2	is	HER2	specific	and	can	visualize	HER2-overexpressing	tumours	at	24	or	48	h	p.i.	with	PET/CT	
imaging.	The	lower	projected	radiation	absorbed	doses	for	64Cu-NOTA-F(ab')2	compared	to	111In-BzDTPA-
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with	SPECT	 (In-111)	or	PET	 (F-18,	Ga-68).	 	 The	peptide	 showed	extremely	high	kidney	 retention	when	
radiolabelled	with	radiometals,	but	this	was	not	seen	with	the	F-18	analogue.		Due	to	anticipated	dose-











was	 enhanced	when	 radiolabelled	with	 a	 high	 LET	particle	 emitter.	Discussion/Conclusion:	The	αvβ6-
specific	 peptide	 when	 radiolabelled	 with	 a	 high-LET	 particle	 emitter	 shows	 promise	 as	 an	 agent	 for	
targeted	radionuclide	therapy.	
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in	 silico	 values,	 and	 is	 applicable	 independently	 of	 target	 and	 chemotype.	 It	 is	 a	 useful	 index	 at	 the	
beginning	of	a	project,	and	facilitates	the	selection	of	the	most	promising	scaffold	for	further	optimization.	
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vitro	 experiments	 with	 BODIPY-C16	 are	 conducted	 to	 investigate	 the	 applicability	 the	 dual-modality	
imaging	probe.	Results:	BODIPY-C16	could	be	radio-labeled	in	a	Lewis	Acid	assisted	F-18/F-19	exchange	




TGL	 was	 also	 successful	 (60%	 yield,	 >97%	 purity).	 Discussion/Conclusion:	 First	 experiments	 implied	
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Influence	 of	 the	 fluorescent	 dye	 on	 the	 tumor	 targeting	 properties	 of	 dual-labeled	 HBED-CC	 based	
PSMA	inhibitors	





Introduction:	 Image-guided	 cancer	 surgery	 using	 fluorescence	 imaging	 has	 high	 clinical	 impact	 and	
already	shows	potential	to	improve	the	outcome	of	oncological	surgery	(1).	As	first	clinical	experiences	
with	the	68Ga-labeled	PSMA-targeting	inhibitor	Glu-urea-Lys-Ahx-HBED-CC	(PSMA-11)	demonstrated	high	
and	 specific	 tracer	 uptake	 in	 prostate	 cancer	 lesions	 a	 fluorescence	 dye	 conjugate	 of	 PSMA-11	might	
represent	a	promising	bimodal	tracer.	The	combination	of	preoperative	staging	by	means	of	PET/CT	and	
PET/MRI,	followed	by	image-guided	surgery	will	further	improve	the	accuracy	of	detecting	PSMA-positive	








all	 conjugates,	 which	 is	 in	 line	 with	 the	 values	 obtained	 with	 the	 reference	 68Ga-PSMA-11.	 The	
radiolabeled	fluorescent-dye	conjugates	showed	specific	cell	uptake	and	were	effectively	internalized	into	








pre-,	 intra-	 and	 post-therapeutic	 identification	 of	 metastases	 with	 one	 and	 the	 same	 molecule.	
References:	(1)	Brouwer	O.	R.,	et	al.	[2014],	Eur	Urol	65:	600-609		
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Introduction:	 Melanoma	 is	 a	 highly	 malignant	 cutaneous	 tumor	 of	 melanin-producing	 cells.	 Early	
detection	of	melanoma	is	the	best	way	to	reduce	mortality.	Several	radiolabeled	 imaging	probes	have	
been	 evaluated	 for	 melanoma	 imaging.	 MEL050	 is	 a	 synthetic	 benzamide-derived	 molecule	 that	
specifically	binds	to	melanin	with	high	affinity.	Our	aim	was	to	implement	a	fully	automated	radiosynthesis	
of	 [18F]MEL050,	 including	 HPLC	 purification	 and	 formulation,	 using	 for	 the	 first	 time,	 the	 AllInOne	
radiosynthesis	 platform	 (Trasis,	Ans,	Belgium),	 and	 to	 validate	 this	 PET	 radiotracer	 in	 vivo	 in	 a	mouse	
model	of	melanoma.	Materials	&	Methods:	[18F]MEL050	was	synthesized	using	a	one-step	bromine-for-
fluorine	 nucleophilic	 heteroaromatic	 substitution.	 Briefly,	 [18F]MEL050	 was	 prepared	 from	 a	 bromo-
precursor,	using	no-carrier-added	18F-KF-Kryptofix	222	(dimethylformamide,	150°C,	6	min),	followed	by	
preparative	HPLC	purification	(C18	column	(300x7.8	mm,	7	μm),	isocratic	elution	with	acetonitrile/20	mM	
ammonium	 bicarbonate	 (20:80,	 v/v),	 3.0	 ml/min)	 and	 cartridge-reformulation	 (Sep-Pak®	 Plus	 C18	
environmental)	of	the	collected	fraction.	Radiochemical	and	chemical	purity,	stability	and	specific	activity	





2h	after	 tracer	 injection.	 The	maximum	percentage	of	 [18F]MEL050	 Injected	Dose	per	 g	of	 lung	 tissue	
(%ID/g	Max)	was	determined	using	ROIs	manually	drawn	on	1h-post	injection	PET	images,	and	correlated	
to	 ex-vivo	 findings.	 Results:	 The	 fully	 automated	 radiosynthesis	 of	 [18F]MEL050	 required	 an	 overall	
radiosynthesis	time	of	60	min,	with	an	end-of-synthesis	yield	of	20-26%	(n=12).	Isocratic	semi-preparative	
HPLC	 allowed	 efficient	 separation	 of	 [18F]MEL050	 from	 the	 reaction	 mixture.	 The	 radiotracer	 was	
consistently	produced	with	radiochemical	purity	higher	than	99%.	The	specific	activity	was	in	the	range	of	
177-325GBq/µmol	 and	 the	 product	 stability	 was	 maintained	 at	 RCP>98%	 over	 6	 h.	 PET/CT	 images	
retrieved	known	biodistribution	of	 [18F]MEL050	 in	mice,	and	allowed	clear	visualization	of	<1mm	 lung	
tumours	 with	 [18F]MEL050	 %/ID/g	 Max	 of	 4.7±2.6%.	 Discussion/Conclusion:	 We	 successfully	
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binding	motif	 Glu-NH-CO-NH-Lys	was	 synthesized	 by	 a	well-established	method	 (4)	 using	 solid	 phase	
chemistry	and	subsequently	an	amino	acid	linker	was	built	up	by	fmoc-based	solid	phase	peptide	synthesis	
(SPPS).	 The	 non-radioactive	 reference	 compounds	 were	 also	 prepared	 analogically	 and	 eventually	
conjugated	 by	 6-fluoronicotinic	 acid.	 After	 separation	 from	 the	 resin	 and	 deprotection	 the	
peptidomimetics	were	labeled	using	the	TFP-ester	of	6-[18F]fluoronicotinic	acid	as	prosthetic	group.	The	
Ki	values	of	all	compounds	were	determined	by	competitive	binding	assays	on	PSMA-positive	LNCaP	cells	
against	 68Ga-PSMA-10	 (5)	 using	 the	 respective	 cold	 reference	 compounds.	 Additionally,	 the	 cellular	
internalization	of	the	radiofluorinated	ligands	was	determined.	Results:	All	18F-labeled	PSMA-inhibitors	
presented	 in	 this	 study	 showed	 low	 nanomolar	 affinities	 towards	 PSMA,	 usually	 paired	 with	 high	
internalization	 ratios	 of	 more	 than	 15	 %,	 shown	 in	 vitro.	 Among	 those	 PSMA-1007	 showed	 an	
outstandingly	high	internalization	ratio	of	about	70	%	while	the	Ki	was	in	the	typical	range	(6	nM).	Hence	
PSMA-1007	was	further	evaluated	in	vivo.	The	organ	distribution	showed	a	high	and	specific	tumor	uptake	
of	 8.0±2.4	 %ID/g.	 Finally,	 the	 PSMA-targeting	 potential	 of	 PSMA-1007	 was	 further	 demonstrated	 by	
dynamic	 µPET	 experiments.	 Discussion/Conclusion:	 Based	 on	 our	 experience	 with	 PSMA-617	 and	
preliminary	 results	we	developed	a	 series	of	 radiofluorinated	PSMA	 inhibitors	with	high	affinities	 and	
internalization	ratios.	Among	those	a	promising	candidate	for	further	translation	into	the	clinic	has	already	
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Mansour	 Nematallah,	 Paquette	 Michel,	 Ait-Mohand	 Samia,	 Dumulon-Perreault	 Véronique,	 Lecomte	
Roger,	Guérin	Brigitte.	
Introduction:	 The	 Gastrin-Releasing	 Peptide	 Receptor	 (GRPR)	 is	 overexpressed	 in	 a	 wide	 variety	 of	
prostate	 cancers,	 hence	 its	 interest	 as	 a	 potential	 biomarker.	 As	 such,	 previous	 work	 used	 different	
radiolabeled	GRPR-binding	peptides	to	specifically	target	tumors	in	vivo	(1,	2).	Recently,	we	synthesized	a	
novel	 bifunctional	 chelator	 bearing	 hydroxamic	 acid	 arms,	 called	 DOTHA2,	 for	 which	 our	 group	














p<	 0.05	 and	 p	 <	 0.01	 at	 30	 min).	 Discussion	 /	 Conclusion:	 The	 use	 of	 [64Cu]-DOTHA2-PEG-RM26	 is	
promising	for	visualizing	prostate	tumors.	These	preliminary	data	suggest	that	DOTHA2	can	be	used	to	
develop	 many	 other	 peptide-	 and	 protein-derived	 PET	 tracers.	 References:	 1.	 Fournier	 P,	 Dumulon-
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Fernandez-Maza	 L1,	 Rivera-Marrero	 S2,	 Prats	 Capote	 A3,	 Parrado-Gallego	 A1,	 Fernandez-Gomez	 I1,	

















radioactivity	measured	 in	 a	 well	 counter.	 RadioTLC	 analysis	 of	 plasma	were	 performed	 for	 the	 same	
purpose	 in	 silicagel	 60	 and	mobile	 phase	 of	 acetonitrile/water	 (95/5).	 20µL	 of	 each	 supernatant	was	
analysed	 by	 HPLC-RP	 using	 a	 C18	 column	 and	 acetonitrile/water	 (75/25)	 as	mobile	 phase	 to	 identify	
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Figure	 1.	 Radiochemical	 synthesis	 followed	 by	 biodistribution	 baseline	 and	 blocking	 and	 time	 activity	
curves	of	microPET	scans	in	rats.	
Materials	 and	 Methods:	 Synthesis	 of	 5-cyano-N-(4-(4-methylpiperazine-1-yl)-2-(4-methylpiperidin-1-
yl)phenyl)furan-2-carboxamide	 and	 5-cyano-N-(2-(4-methylpiperidine-1-yl)-4-(piperazine-1-
yl)phenyl)furan-2-carboxamide	were	 done	 according	 to	 literature	methods	with	 slight	modifications	3.		
[11C]-methyl	triflate	reacts	with	the	precursor	in	presence	of	a	base	at	room	temperature	for	2	minutes	
providing	carbon-11	radiolabeled	[11C]BA-1	(Figure	1)	which	was	purified	by	using	reversed-phase	high	
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Biodistribution	 study	 shows	 high	 tracer	 uptake	 in	 brain	 (4	 %	 ID	 4	 at	 2	 min),	 with	 both	 renal	 and	
hepatobiliary	excretion.	High	lung	uptake	was	observed	with	(14	%	ID	at	2	min	p.i.).	Blocking	with	cold	
compound	did	not	result	in	any	blocking	effect	in	brain	but	we	observed	blocking	in	peripheral	organs	like	







Reviews,	 33,	 No.	 3,	 599-636.	 3.	 C.	 R	 Illig	 et	 al,	 Discovery	 of	 novel	 FMS	 Kinase	 inhibitors	 as	 anti-
inflammatory	agents	(2008),	Bioorganic	&	Medicinal	Chemistry	Letters,	18,	1642-1648.	
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animal	 PET/CT/MR	 experiments,	 rats	 were	 anesthetized	 by	 isoflurane.	 25min	 after	 [18F]FE@SNAP	 iv	














RATIO	 Baseline	 Blocking	 P-values	
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phenotype	 of	 activated	 microglia,	 and	 is	 not	 expressed	 on	 macrophages	 and	 other	 brain	 cells	 [2].	








Results:	Compound	5	 and	precursors	3	and	6	were	 successfully	 synthesised.	 [11C]5	was	obtained	 in	 a	
radiochemical	 yield	 of	 10±2	 %	 (corrected	 for	 decay,	 calculated	 from	 [11C]CO2	 (n=6)),	 and	 high	
(radio)chemical	purity	(≥98%)	and	specific	activity	(79±32	GBq·µmol-1	(n=6)).	In	in	vitro	autoradiography	
studies	 of	 the	 healthy	mouse	 brain,	 [11C]5	 could	 be	 blocked	 (81%)	with	 ticagrelor,	 indicating	 specific	
binding	to	P2Y12R.	However,	rapid	metabolism	in	rat	plasma	was	observed	with	only	30±4%	(n=3)	of	[11C]5	
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of	 cancers	 (ovarian,	 breast,	 prostate,..)	 to	neurological	 deficiencies	 (Alzheimer’s	 disease,	Huntington’s	
disease,	 amyotrophic	 sclerosis,..)	 [1,2].	 Still	 many	 characteristics	 and	 functions	 of	 HDAC6	 in	 these	
pathologies	 are	 unrevealed.	 Hence,	we	 aim	 to	 develop	 a	 selective	 HDAC6	 PET	 tracer	 to	 visualize	 the	
dynamics	of	HDAC6	in	normal	and	disease	states.	Recently,	Lu	and	coworkers	synthesized	[11C]KB631,	a	
highly	 potent	 (IC50=1.4	 nM)	 and	 selective	 (3700-fold	 selectivity	 against	 HDAC1)	 PET	 tracer	 for	 HDAC6	
imaging	 in	 the	 brain,	which	 showed	 similar	 pharmacokinetic	 properties	 as	 tubastatin	A	 [3].	 However,	





2,	10,	30	and	60	min	 (n	=	3	 /	 time	point)	post	 injection	 (p.i.).	Organs	and	 tissues	were	harvested	and	
radioactivity	was	counted	in	a	gamma-counter.	Autoradiography	studies	were	carried	out	with	[11C]KB631	
on	wild-type	Wistar	rat	brain	tissue	and	PC3/LNCaP	prostate	tumor	slices.	Slices	were	incubated	with	18.5	
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Discussion/Conclusion:	 We	 successfully	 radiolabeled	 and	 evaluated	 a	 potential	 carbon-11	 labeled	
radiotracer	for	in	vitro	and	ex	vivo	visualization	of	HDAC6.	However,	biodistribution	studies	indicated	low	
brain	uptake,	peripheral	potency	 still	 needs	 to	be	 further	examined.	Autoradiography	 studies	 showed	







urine kidneys liver stomach
intestin
es brain blood carcass lungs spleen	 heart bone
pancre
as muscle
2	min	p.i. 0,53 17,4 30,1 1,2 8,9 0,08 7,9 31,5 2,54 0,74 1,24 4,51 1,23 27,53
10	min	p.i. 5,0 7,2 25,8 1,2 15,4 0,12 4,9 38,2 1,74 0,46 0,60 5,07 0,93 25,29
30	min	p.i. 9,3 5,6 20,2 2,2 31,1 0,08 4,0 26,6 1,04 0,23 0,37 3,10 0,76 15,20











2	min	p.i. 10	min	p.i. 30	min	p.i. 60	min	p.i.
Fig.2	Biodistribution	study	in	NMRI-mice	[11C]KB631	at	2,	10,	30	and	60	min	p.i.		
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Introduction:	 (R)-[11C]verapamil	 is	 widely	 used	 as	 a	 PET	 tracer	 for	 investigating	 P-glycoprotein	 (P-gp)	
function	 in	 patients	 with	 epilepsy,	 Alzheimer´s	 disease	 and	 other	 neurodegenerative	 diseases	 [1].	
















analysis	 for	1	and	2	 (non-deuterated	analogues)	and	1b	and	2b	 (deuterated	analogues)	 in	plasma	and	
brain.	Results:	1b,	2b,	3b	and	4b	were	obtained	in	a	radiochemical	yield	of	3,	6,	5	and	10%,	respectively,	
a	purity	>98%	and	a	specific	activity	>80	GBq·µmol-1.	Results	of	the	metabolite	analysis	are	presented	in	





and	still	need	 to	be	evaluated	 for	metabolic	 stability.	Reference:	 [1]	Raaphorst	RM	et	al.,	 [2015],	Clin	
Pharmacol	 Ther	 97	 (4):	 362-371	Acknowledgements:	 This	 project	 is	 supported	 by	 STW	 (OTP-project	
11741)	
OP36	
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106	 EGFR/cell)	 and	MDA-MB-231/H2N	 (105	 EGFR/cell)	 cells	 to	 Cy3-EGF-Au-PEG	NPs.	 111In-EGF-Au-PEG	
(MW:	6000)	and	111In-EGF-Au	NPs	were	chosen	for	SPECT	imaging	and	biodistribution	studies	using	MDA-
MB-468	xenograft-bearing	mice.	Results:	Successful	PEGylation	was	confirmed	by	DLS	and	zeta	potential	
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after	 incubation	in	human	and	rat	sera	as	well	as	 in	rat	 liver	homogenate;	a	fast	degradation	of	2	was	
detected	in	kidneys	homogenate.	1	retains	a	high	receptor	affinity	(Kd=7.1	±	0.5	nM).	Biodistribution	data	
of	1	display	a	favorable	pharmacokinetic	profiles	characterized	by	a	fast	blood	clearance	and	elimination	








This	 research	 was	 supported	 by	 MIUR	 through	 PRIN	 20097FJHPZ-004	 and	 FIRB	 “RINAME”2010-
RBAP114AMK.	
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expression	 using	 PET.	 Here	 we	 present	 all	 data	 (quality	 control,	 toxicological	 study,	 and	 dosimetry	
estimation)	necessary	to	initialize	clinical	studies,	the	establishment	of	the	remote	controlled	synthesis,	
and	 data	 from	 the	 phase	 I	 clinical	 study.	Methods:	 Labelling	 was	 carried	 out	 in	 a	 remote	 controlled	
synthesis	 unit	 under	 clean	 room	 conditions.	 Quality	 control	 included	 TLC,	 HPLC,	 GC,	 pH	 control,	 Ge-
breakthrough,	half-life,	endotoxin	content,	and	control	of	sterility.	Storage	stability	after	4	h	was	studied	
and	dose	estimations	based	on	animal	data	were	carried	out	using	OLINDA.	Sprague-Dawley	rats	were	
used	 for	 an	 extended	 single	 dose	 toxicity	 study.	 The	 phase	 I	 clinical	 study	 included	 9	 patients	 with	
hepatocellular	carcinoma	(HCC).	Static	scans	at	5,	30,	and	60	min	p.i.	including	5	bed	positions	each	were	
performed	using	the	Discovery	690	PET/CT.	Blood	was	sampled	30	and	60	min	p.i.	and	urine	60	min	p.i.	
and	 used	 for	 stability	 studies	 via	 HPLC.	 Results:	 [68Ga]NODAGA-RGD	 could	 be	 produced	 in	 high	
radiochemical	yield	and	 radiochemical	purity	 (HPLC	and	TLC	>99%).	The	pH	 in	 the	 final	 isotonic	 saline	
formulation	 was	 approx.	 6.	 Ethanol	 content	 was	 between	 2.5	 and	 3.0%	 v/v.	 No	 detectable	 68Ge-
germanium	was	 found.	 LAL	 test	 revealed	 0.7	 EU/ml.	 Sterility	 tests	 showed	 that	 all	 samples	 met	 the	
specifications	according	to	Ph.	Eur..	No	radiolysis	of	the	tracer	was	found	in	the	formulated	solution.	The	
single	dose	toxicity	study	showed	that	the	compound	was	well	tolerated	in	animals.	This	was	confirmed	
by	 the	 clinical	 study	 where	 no	 severe	 side	 effects	 were	 observed.	 High	 metabolic	 stability	 of	
[68Ga]NODAGA-RGD	was	found	based	on	the	analysis	of	blood	and	urine	samples.	The	static	scans	showed	
rapid	tracer	elimination	from	the	body	with	low	background	activity	in	almost	all	organs.	The	calculated	
effective	dose	was	21.5±5.4	µSv/MBq.	Unfortunately,	 the	 investigated	 tumors	did	not	show	 increased	
tracer	accumulation	indicating	no	or	low	integrin	αvβ3 expression.	Conclusion:	This	study	revealed	that	
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However,	 GMP-z	 does	 not	 allow	 to	 synthesize	 radiopharmaceuticals	 for	 clinical	 trials	 or	 therapeutic	
applications,	in	which	case	the	European	GMP	applies.	At	the	MUMC,	a	growing	interest	in	performing	in-
house	clinical	trials	with	new	radiopharmaceuticals	and	in	the	synthesis	of	radiotherapeuticals	led	to	the	
decision	 of	 upgrading	 the	 current	 Radiopharmacy	 facility.	 Several	 restrictions	 applied:	
radiopharmaceuticals	will	not	be	sold	to	third	parties	and	the	surface	area	of	the	entire	facility	is	limited	
to	55	m2	(including	the	production	lab,	QC	lab	and	separate	sluices	for	personnel	and	goods).	Additionally,	
the	 facility	 had	 to	 allow	 both	 preparation	 of	 routine	 99mTc-compounds	 as	 well	 as	 GMP-grade	
radiopharmaceuticals.	This	study	examines	the	time	line	of	implementation	for	such	a	small	scale	facility	
and	may	be	relevant	to	other	hospitals	considering	to	comply	with	this	regulation.	Materials	&	Methods:	







second	 phase	 of	 the	 reconstruction	 (setting	 up	 of	 a	GMP-compliant	 cleanroom)	 is	 scheduled	 to	 start	
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Introduction:	 Good	 Manufacturing	 Practice	 (GMP)	 sets	 strict	 requirements	 for	 the	 manufacturing	
conditions,	synthesis	and	quality	of	radiopharmaceuticals.	Robust	production	and	quality	control	methods	
for	radiopharmaceuticals	are	essential	 for	diverse	and	effective	clinical	utilization	of	Positron	Emission	
Tomography	 (PET).	This	presentation	describes	 the	set	up	procedure	of	a	new	radiopharmaceutical	 in	
Turku	 PET	 Centre	 (TPC).	 All	 issues	 other	 than	 directly	 related	 to	 GMP	 such	 as	 toxicology,	 labeling	
chemistry,	analytical	methods	or	documentation	for	the	authorities	(i.e.	IMPD)	are	not	discussed	here.	




























according	 to	 a	 written	 validation	 plan.	 In	 addition	 bioburden	 (number	 of	 bacteria	 living	 on	 the	 drug	
solution	 before	 sterilization)	 must	 be	 determined.	 The	 aseptic	 processing	 of	 operators	 must	 also	 be	
confirmed	by	performing	media	 fills	 (the	performance	of	 an	aseptic	manufacturing	procedure	using	a	
sterile	 microbiological	 growth	 medium	 in	 place	 of	 the	 drug	 solution).	 At	 TPC	 the	 process	 validation	
includes	 three	consecutive	process	validation	batches	which	 shall	 fulfill	 all	 specifications	 for	 the	given	
radiopharmaceutical.	This	also	qualifies	the	operator	for	production.	Additional	batches	must	be	done	in	
order	 to	 qualify	 more	 operators.	 Finally,	 process	 validation	 and	 documentation	 is	 compiled.	 Process	
validation	report,	method	description	for	preparation	and	quality	control	and	master	batch	record	are	
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interpretation	 of	 diseases	 and	 abnormalities	 in	 vivo.	 Dual	modality	 PET/MRI	 imaging	 agents,	 such	 as	
radiolabeled	 magnetic	 nanoparticles,	 are	 promising	 candidates	 for	 a	 number	 of	 diagnostic	 and	
therapeutic	applications	(i.e.	MRI-magnetic	hyperthermia	and	radiotherapy).	The	aim	of	the	present	study	
is	 to	evaluate	 the	efficacy	of	 68Ga	 labeled	 Fe3O4	 superparamagnetic	 iron	oxide	nanoparticles	 (SPIONs)	
coated	 with	 DPD	 phosphonate,	 as	 potential	 PET/MRI	 imaging	 agents.	Materials	 &	Methods:	 SPIONs	
coated	with	 biocompatible	DPD-phosphonate	were	 radiolabeled	with	 positron-emitting	Gallium-68	 to	
quantify	the	accumulation	of	the	nanoparticles	in	vivo.	In	vitro	stability	studies,	in	PBS,	saline	and	human	






Fe3O4-DPD	 SPIONs	 and	 free	 68Ga-acetate	 were	 also	 compared,	 indicating	 different	 pharmacokinetic	
behavior	for	68Ga-acetate,	with	no	target	tissue	and	excretion	via	 the	kidneys.	Conclusion:	 68Ga-Fe3O4-
DPD	 SPIONs	 demonstrated	 high	 radiolabeling	 efficiency	 and	 in	 vitro	 stability	 and	 satisfactory	 in	 vivo	
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injection	of	 cell	 suspension	of	 E.	 coli;	 acute	phase	of	 infection	was	evoluted	 for	 3-4	days).	 PET/X-RAY	
Genisys4	(Sofie	Bioscience,	USA)	was	used	for	noninvasive	PET	imaging	with	subsequent	reconstruction	
of	 imaging	 and	 their	 analysis	 (value	 of	 clearance,	 distribution	 volume).	 Scanning	 time	 is	 10	 min.	
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inflammation	 early	 (for	 30-60	 min	 after	 injection).	 Pharmacokinetic	 parameters	 proved	 it.	
Discussion/Conclusion.	 There	 was	 no	 statistically	 significant	 difference	 between	 68Ga-citrate	
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Introduction:	 In	 the	 installation	 of	 methionine	 as	 our	 latest	 tracer	 we	 chose	 the	 Eckert	 and	 Ziegler	






column	with	 70:30:0.02,	MeOH:H2O:HCOOH	 eluent	 was	 employed.	Results:	During	 later	 analyses	 for	
residual	solvents	 in	connection	with	a	GC-PQ,	THF	was	 found	present	 in	 the	product,	3-4	 times	above	
recommended	level.	The	HPLC	method	in	the	Ph.Eur	 is	10	minutes,	however,	by	 increasing	acquisition	
time,	a	radio	peak	appeared	at	about	18	minutes	in	the	chromatogram.	This	peak	was	about	10-15%	of	
total	 radio	 signal,	meaning	 the	 required	 radio	purity	 limit	 in	 Ph.Eur	was	not	met.	When	analysing	 for	
enantiomeric	purity,	which	was	not	initially	done,	about	12%	of	the	d-enantiomer	was	found,	not	meeting	





achieved	 and	 the	 radio	 purity	 limits	 described	 by	 the	 Ph.Eur	 monograph	 was	 finally	 met.	 Different	
protocols	 are	 called	 for	 in	 the	 initial	 phase	 dissolving	 the	 precursor	 in	 ethanol	 and	 NaOH	 solution,	
however,	tweaking	these	had	little	effect	of	the	enantiomeric	purity.	Different	batches	of	precursor	was	
later	analysed	for	enantiomeric	purity.	Large	discrepancies	were	found	between	batches	which	directly	
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new	 developments	 in	 prostate	 cancer	 imaging	 and	 therapy.1,2	 In	 collaboration	 with	 IBA,	 we	 have	
established	 an	 automated	 synthesis	 of	 68Ga-labelled	 peptides	 including	 68Ga-DOTA-TATE/-NOC,68Ga-
PMSA-11	and	68Ga-PSMA-617	on	Synthera®.	Materials	&	Methods:	During	the	tests,	an	IBA	Synthera®	and	
the	new	Synthera®	Extension	module	were	used.	68Ga	was	obtained	initially	from	an	old	iGG	100	generator	
in	5	mCi.	The	 final	 tests	were	carried	out	 in	combination	with	a	new	GalliaPharm	68Ge/68Ga	generator	
loaded	with	50	mCi.	A	modified	standard	nucleophilic	IFPTM	(IFP™	FDG)	was	designed	for	the	synthesis	
process.	 Synthera®	 Extension	was	 used	 for	 the	 elution	 of	 the	 generator.	 The	 eluate	was	 loaded	 on	 a	
Chromafix	PS-H+		cartridge	and	the	hydrochloric	acid	waste	 -	which	contains	most	of	 the	 68GeCl4	 -	was	
transferred	into	the	waste	container.	The	activity	was	eluted	from	the	cation	exchange	cartridge	using	a	
solution	of	5	M	sodium	chloride	in	0.1	N	hydrochloric	acid3	and	transferred	directly	into	the	reaction	vessel	









final	 solution	was	5	 to	5.5.	Ethanol	 content	was	<	10%.	Discussion/Conclusion:	We	have	developed	a	
dedicated	disposable	IFP	cassette	for	the	IBA	Synthera®	and	Synthera®	Extension	modules,	which	delivers	
all	 common	 68Ga-tracers	 in	 high	 yield.	 	 The	 use	 of	 dedicated	 single	 -use	 Gallium-68	 IFPTM	 allows	 for	
production	of	18F-FDG	on	the	same	module	with	no	cross-contamination.	References:	1	Afshar-Oromieh	
A,	Hetzheim	H,	Kratochwil	C,	Benesova	M	et	al.,	[2015],	JNM	56:	1697-1705.	2	Benešová	M,	Schäfer	M,	
Bauder-Wüst	 U,	 Afshar-Oromieh	 A	 et	 al.,	 [2015],	 JNM	 56:	 914-920.	 3	Mueller	 D,	 Klette	 I,	 Baum	 R	 P,	
Gottschaldt	M	et	al.,	[2012],	BC	23:	1712-1717	
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is	produced	using	a	cyclotron	 that	accelerates	deuterons	onto	a	 target	 filled	with	 14N2	with	a	 trace	of	
oxygen.		Nowadays,	cyclotrons	have	been	developed	that	are	only	capable	of	accelerating	protons.	This	
abstract	 describes	 the	 performance	 of	 Cyclone	 18	 twin	 from	 IBA,	 which	 accelerate	 only	 protons,	 for	
production	and	administration	of	 [15O]H2O.	Methods:	The	Cyclone	18	 twin	 from	 IBA	 is	 a	 fixed	energy	
cyclotron	using	18	MeV	protons	 in	which	H-	particles	are	accelerated	and	converted	 into	protons	 (H+).	
Bombardment	with	protons	of	the	special	designed	target	filled	to	25	bar	takes	place,	initiating	the	nuclear	
reaction:	 15N(p,n)15O.	 [15O]H2O	was	 produced	 by	 conversion	 of	 the	 [15O]O2	 using	 a	 new	 designed	 IBA	












Cyclone	18	 and	dedicated	 chemistry	module	 from	 IBA	was	described	and	qualified	 according	 to	GMP	
regulations.	It	was	demonstrated	to	be	suitable	for	clinical	use.		
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phthalocyanine,	 porphyrin	 and	 tetraprol	 derivatives	 are	 come	up	PDT	applications.	 	 Furthermore,	 PSs	
accumulate	 selectively	 in	 the	 tumor	 tissue	compared	 to	normal	 tissue.1,	2	 	Therefore,	 such	compounds	
labeled	with	a	radionuclide	can	be	used	as	a	probe	for	nuclear	imaging.	In	present	study,	we	synthesized	
a	 new	 Subphthalocyanine	 (SubPc)	 and	 Zinc	 phthalocyanine	 [Zn(II)Pc]	 and	 determined	 in	 vitro	 nuclear	






































F,	 Yum	 JH,	 Martínez-Díaz	 M,	 Nazeeruddin	 MK,	 Grätzel	 M,	 Torres	 T,	 [2012]	 C-AEJ	 18:	 6343-6348.	 6.	
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allows	 them	 to	 be	 used	 as	 bifunctional	 agents	 for	 PDT	 and	 nuclear	 imaging.	 In	 the	 present	 study,	
symmetrical	Zn(II)Pc	1	and	unsymmetrically	substituted	Zn(II)Pc	2	were	synthesized	and	examined	as	a	














agent	 for	 lung,	 ovary	 pancreas,	 and	 colon	 tumors.	 However,	 the	 radiolabeled	 Zn(II)Pc	 2	 might	 be	 a	
promising	nuclear	 imaging	agent	for	colon	and	pancreas	tumors,	also	promising	PDT	agent	for	cervical	
tumors.	References:	1.Castano	AP,	Demidova	TN,	Hamblin	MR,	[2004],	PPT	1(4):	279-293.	2.	Juarranz	A,	
Jaen	P,	 Sanz-Rodriguez	F,	Cuevas	 J,	Gonzalez	 S	 [2008],	CTO	10(3):	 148-154.	3.	Plaetzer	K,	Krammer	B,	
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mL/min	 and	 a	 3	 min	 gradient	 of	 30/70	 acetonitrile/0.1%	 TFA.	 The	 sigma-1	 receptor	 imaging	 probe	








By	 injecting	400	kBq	of	 [18F]fluspidine	and	using	 the	different	 flow	cells,	γ-signals	having	a	peak	width	
between	0.13	and	0.20	mm	and	a	peak	intensity	750	-	4400	cps	were	obtained.	The	capillary	holder	(5	nL)	
and	 the	 self-build	 insert	 (2	 nL)	 showed	 a	 comparable	 peak	 width,	 but	 differentiated	 sensitivity.	 To	
determine	 the	minimum	detectable	 level	 samples	between	170	kBq	and	8	kBq	of	 [18F]fluspidine	were	
injected;	with	15	kBq	of	[18F]fluspidine	a	good	signal	to	background	ratio	of	6:1	was	achieved.	
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Introduction:	Several	studies	are	available,	which	highlight	the	use	of	Schiff	base	ligands	for	radio-labeling,	
but	very	 little	work	has	been	reported	which	has	used	Marcepto	compounds,	although	 it	 is	desired	to	
include	such	compounds	in	the	design	of	radiopharmaceuticals	due	to	their	importance	in	the	biological	
system.	Materials	and	methods:	Equimolar	L	–	cysteine	and	salicylaldehyde	in	distilled	water	and	ethanol	
were	heated	at	40°C	 to	 form	a	white	colored	 ligand.	The	product	 formed	was	analyzed	using	FT	–	 IR,	
thermo	 gravimetric	 analysis	 and	 elemental	 analysis	 at	 Fc	 College.	 Radiolabeling	 of	 the	 ligand	 was	
performed	at	SKMCH&RC	using	99mTc	from	99Mo	generator.	SnCl2.H2O	was	used	as	a	reducing	agent	at	
STP.	Radio	TLC	was	performed	using	SG	plates	and	0.9%	NaCl	and	acetone	as	the	mobile	phases.	Geiger	
Muller	 counter	 detected	 the	 counts	 on	 the	 SG	plates	 and	 radiolabeling	 efficiency	 of	 the	 product	was	





After	 optimizing	 various	 parameters	 effective	 radiolabeling	 up	 to	 88	 %	 was	 achieved	 at	 pH	 5,	 using	
lyophilized	 tin	 chloride	 pyrophosphate	 cold	 kit	 in	 NaCl	 (0.9%).	 Animal	 study	 was	 carried	 out	 for	 Bio	


















18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
April 07-10, 2016  Salzburg, Austria 
Page 64	
Fig. 2 
Fig. 3 Fig. 4 
Reference:	1.	MacDonald,	L.	G.,	Brown,	D.	H.,	Morris,	J.	H.,	&	Smith,	W.	E.	(1982).	Copper	Schiff	base	
complexes	with	polyfunctional	amino	acids.	Inorganica	Chimica	Acta,	67,	7-12.	
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Introduction:	Radiolabelled	 nanoparticles	 have	 gained	 a	 widespread	 application	 in	 the	 diagnosis	 and	
therapy	 of	 several	 diseases	 (inflammation/infection,	 cancer,	 and	 others).	 	 PLGA	 Nanoparticles	 (NPs)	
prepared	by	 solvent	 emulsion	evaporation	method	 [1]	 have	 shown	more	 suitable	 characteristics	with	
regard	 to	 those	 produced	 by	 nanoprecipitation:	 better	 size,	 a	 higher	 homogeneity	 and	 higher	
encapsulation	 efficiency.	 The	 combination	 of	 99m	 Tc	 +	 PLGA	 nanoparticles	 (platforms	 with	 excellent	
biodegradability	and	biocompatibility)	could	allow	obtaining	a	suitable	nanosystem	for	theranosis.	The	
aim	of	the	present	work	is	to	optimize	the	radiolabelling	of	PLGA	nanoparticles	with	99mTc.	Materials	and	






start.	 Using	 a	 solution	 of	 pyridine:	 acetic	 acid:	 water	 (3:	 5:	 15),	 radiocolloids	 remained	 at	 start,	 NPs	
migrated	 with	 Rf	 =	 0.3	 and	 free	 pertechnetate	 moved	 with	 Rf	 =	 0.7-0.8	 [2].	 Results:	Using	 1	 μg	 of	
SnCl2*2H2O	as	a	reducing	agent,	PLGA	nanoparticles	(without	surface	modification)	were	labeled	with	99m	
Tc	with	 a	 yield	 ≥	 90	%.PLGA	nanoparticles	 size	 ranged	 from	160-180	nm	 in	 diameter	with	 an	 electric	
surface	of	-36	mV.	After	radiolabelling,	particles	increased	in	size	up	to	a	diameter	≈	380	nm.	Conclusions:	
Results	obtained,	indicate	that	the	procedures	of	nanoparticle	synthesis,	radiolabelling	and	quality	control	
were	 reproducible	 and	 right	 to	 design	 a	 biodegradable	 nanosystem	 suitable	 for	 in	 vivo	 theranosis.	
References:	 [1]	 Martín-Banderas	 L,	 Sáez-Fernández	 E,	 Holgado	 MÁ,	 Durán-Lobato	 MM,	 Prados	 JC,	
Melguizo	C,	Arias	JL.	Int	J	Pharm.	2013	Feb	25;443(1-2):103-9.	[2]	Snehalatha	M,	Kolachina	V,	Saha	RN,	
Babbar	AK,	Sharma	N,	Sharma	RK.	J	Pharm	Bioallied	Sci.	2013	Oct;5(4):290-7.	
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widely	 studied	 for	 the	 development	 of	 radiopeptides	 for	 application	 in	 prostate	 cancer	 imaging.	 To	
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dimethoxyphenyl)-5-fluorobenzothiazole	 (PMX	 610)	 exhibited	 very	 potent	 (GI50	 <	 0.1	 nM)	 antitumor	
properties	in	vitro	in	human	breast	cancer	cell	lines.	Based	on	that	scaffold	we	recently	suggested	18F-











EtOH	 allowing	 for	 complete	 removal	 of	 the	 precursor.	 The	 product,	 [18F]FEDMBT,	was	 recovered	 by	
successive	elution	of	the	cartridge	with	2	and	1	mL	of	55%	aq.	EtOH.		
Results	 Under	 optimal	 reaction	 conditions	 (see	 figure)	 a	 high	 18F-incorporation	 rate	 of	 80-85%	 was	
achieved.	The	HPLC	purification	afforded	the	product	in	>99%	radiochemical	purity	and	RCY	of	55%	(decay	
corrected).	 Isolated	product	 fraction	was	mixed	with	 phosphate	 buffered	 saline	 to	 adjust	 the	 pH	 and	
ethanol	concentration,	without	final	re-formulation	step.	Fractionated	SPE	purification	afforded	product	
with	>99%	RCP	and	60%	RCY	(decay	corrected).	While	SPE	technique	allowed	for	complete	removal	of	
precursor,	a	minor	chemical	 impurity	 (not	 identified)	 remained	 in	 the	 final	 formulation.	Work	 is	being	
undertaken	now	to	resolve	this	 issue.	 	Discussion/conclusion:	An	optimized	synthesis	of	[18F]FEDMBT	
afforded	product	with	radiochemical	purity	and	high	yield.	It	can	be	easy	automated	using	TracerLab	FX-
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technetium	 radioisotopes	 to	 the	 patient	 radiation	 absorbed	 dose	 after	 administration	 of	 four	
radiopharmaceuticals	prepared	with	 technetium-99m	obtained	 from	 the	100Mo(p,2n)99mTc	 reaction.	
Methods:	 The	 internal	 radiation	 absorbed	 doses	 of	 pertechnetate,	 sestamibi,	
hexamethylpropyleneamine	 oxime	 (HMPAO),	 and	 disodium	 etidronate	 (HEDP)	 radiopharmaceuticals,	
were	assessed	considering	both	technetium-99m	prepared	from	the	100Mo(p,2n)99mTc	reaction	as	well	
as	from	generators.	Time-integrated	activity	in	the	main	source	organs	[Ã(rs,TD)]	for	each	radioisotope	
was	 calculated	 using	 the	 radiopharmaceutical	 biokinetic	 models	 published	 by	 the	 International	





Bone	marrow	 is	 the	organ	 that	exhibited	 the	highest	difference	between	 the	dose	obtained	 from	 the	
generator-produced	99mTc	and	the	accelerator-produced	one.	For	example,	HEDP	bone	marrow	dose	
(4.41E-03	mSv/MBq)	showed	an	increase	in	the	of	8.5%	(4.79E-03	mSv/MBq),	11.8%	(4.93E-03	mSv/MBq)	
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Introduction:	 The	 use	 of	 pharmacokinetics	 modeling	 in	 preclinical	 nuclear	 medicine	 is	 very	 limited	
although	 it	 is	 well	 known	 that	 such	 models	 could	 be	 valuable	 tools	 to	 study	 radiopharmaceutical-
properties1.	Nowadays,	 the	preclinical	evaluation	of	new	radiopharmaceuticals	 is	 still	 focused	only	on	
biodistribution	 studies,	 mainly	 because	 of	 the	 lack	 of	 currently	 available	 user-friendly	 specialized	
programs	to	assist	 researchers	 in	calculating	radiopharmacokinetic	parameters.	Methods:	A	dedicated	
spreadsheet	software	to	calculate	pharmacokinetic	parameters	such	as	tracer-biological	half-life	(T1/2),	
mean	 residence	 time	 (MRT)	 for	 each	 compartment,	 as	 well	 as	 the	 fraction	 of	 the	 tracer	 leaving	 the	








been	 integrated	to	calculate	T1/2	and	MRT	 in	 the	studied	organs	of	all	MPIAs.	Subsequently	software	
employs	a	module	with	 implemented	optimization	procedure,	dedicated	to	calculate	the	values	of	the	
TRCs.	Finally,	CoKiMo	calculations	were	validated	by	comparison	with	two	different	software:	Olinda/Exm	
and	 SAAM	 II.	 [99mTcN-(PNP)]+-complexes	 showed	 a	 faster	 blood	 and	 liver	 clearance	 as	 compared	 to	
99mTc-Sestamibi	and	99mTc-Tetrofosmin,	in	agreement	with	some	previous	reported	studies2.	However,	
it	 was	 found	 that	 when	 CoKiMo	 pharmacokinetic	 data	 were	 used,	 a	 wide	 quantitative	 comparison	
between	all	MPIAs	was	possible,	which	in	fact,	was	not	possible	using	only	the	biodistribution	data.	The	
analysis	of	the	results	showed	that		99mTcN-PDTC3	turned	out	to	be	the	best	candidate	for	translation	
into	 clinical	 practice	 due	 to	 its	 rapid	 and	 high	 heart	 uptake,	 and	 fast	 liver	 and	 lung	 clearance,	which	
enabled	an	early	visualization	of	myocardial	tissue.	Conclusion:	CoKiMo	proved	to	be	an	easy	to	use	and	
flexible	specialized	software	to	study	the	kinetic	of	a	great	number	of	pharmaceuticals	labeled	with	an	
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PEtOx	 5kDa,	 µPET	 imaging	 revealed	 rapid	 and	 complete	 blood	 clearance	 of	 [18F]-PEtOx	 5kDa	
(SUV=2.42±0.16	 at	 10min	pi	 and	 SUV=0.27±0.08	 at	 1h	pi).	 Peak	 liver	 uptake	 related	 to	perfusion	was	
reached	 within	 1min	 pi	 (SUV=2.92±0.18)	 and	 quickly	 decreased	 (SUV=0.50±0.03	 at	 10min	 pi	 and	
SUV=0.07±0.00	at	1h	pi)	 indicating	only	minor	contribution	of	the	liver	 in	the	clearance	of	[18F]-PEtOx	
5kDa.	 The	 kidneys	 displayed	 a	 high	 initial	 uptake	 (SUV=5.67±0.87	 at	 3.75min	 pi	 versus	 7.58±2.54	 at	
3.75min	pi	for	[89Zr]-Df-PEtOx	5kDa)	but	where	[89Zr]-Df-PEtOx	5kDa	was	not	cleared	from	the	kidneys	
(SUV=2.36±0.84	 at	 24h	 pi),	 [18F]-PEtOx	 5kDa	 showed	 a	 fast	 and	 almost	 complete	 clearance	
(SUV=0.27±0.08	at	1h	pi	and	SUV=0.12±0.05	at	2h	pi).	Conlusions:	 [18F]-PEtOx	5kDa	 is	quickly	cleared	
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of	 that	 previous	work	we	 have	 investigated	 the	 synthesis	 of	 the	 α-[18F]fluoropropyl-L-DOPA	 via	 18F-
fluorination	of	a	similar	precursor	(I,	Fig.1).		
	






bis((methylsulfonyl)oxy)benzyl)-5-((methylsulfonyl)oxy)pentanoic	 acid	 (Ni-(S)-BBA-(S)-MsO	 propyl-
DOPA(OMs)2	 (I)),	 was	 prepared	 from	 the	 corresponding	 NiII	 complex	 of	 BBA	 Schiff	 base	 with	 (S)-
DOPA.18F-fluorination	 efficiency	 of	 I	 was	 15%,	 with	 room	 for	 optimization.	 Acid	 hydrolysis	 of	 the	
intermediate	afforded	protected	derivative	of	(S)-α-[18F]fluoropropyl-L-DOPA,	but	removal	of	the	mesyl	
protective	groups	proved	problematic	 -	use	of	2M	potassium	methylate	 in	MeOH	 (60oC,	10	min)	was	
ineffective.	 	Discussion/conclusion	The	nucleophilic	 fluorination	of	NiII-based	 labeling	precursor	offers	
potential	 novel	 route	 towards	 a	 new	 derivative	 of	 DOPA	with	 18F-label	 in	 the	 α-fluoropropyl	 group.	
Preparation	of	precursor	employing	methoxy	methoxy	(MOM)	protective	groups	instead	of	mesyl	ones,	
something	 that	 should	 resolve	 the	 deprotection	 problem,	 is	 currently	 in	 progress.	 	 This	 study	 was	
supported	by	SNF	grant	IZ73ZO_152360/1.	References:	1	Huang	C	et	al,	[2013],	Nucl	Med	Biol,	40,	498-
506;	2	Krasikova	R	et	al,	[2015],		EJNMMI,	42,	Suppl.1,	S479-480.	 	
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in	 DCM,	 rt,	 5	min)	 without	 compromising	 the	 RCY.	 No	 intermediate	 purification	was	 required	 in	 the	
process,	that	produced	>99%	radiochemically	pure	3	in	20%	RCY	with	a	specific	activity	>100	GBq/µmol.	
Discussion/Conclusion:	A	simplified	one-pot	 radiosynthesis	of	3	was	developed	 in	which	 intermediate	
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3a,4a-diaza-s-indacene	 (BODIPY)	 as	 a	 fluorescent	 probe	 and	 precursor	 for	 18F-labelling	 to	 develop	
estradiol-based	ligands	for	ER.	The	synthesis	involves	attachment	of	a	BODIPY	moiety	to	the	C17α-position	
of	estradiol	using	Sonogashira	cross	coupling	reaction	of	iodo-BODIPY	and	various	17α-ethynyl	estradiol	
(EE2)	 derivatives.	 Confocal	 laser	 scanning	microscopy	was	used	 to	monitor	 cellular	 uptake	of	 the	 EE2	
conjugates	after	1	h	of	treatment	without	and	with	estradiol	to	block	ER.	Flow	cytometric	analysis	was	
performed	 to	 determine	 the	 relative	 fluorescence	 in	 the	 nuclei.	 Results:	 The	 Sonogashira	 coupling	
reaction	 of	 EE2	 derivatives	 with	 iodo-BODIPY(1:1	 molar	 ratio)	 in	 THF/toluene	 (1/2)	 and	 using	
PdCl2(PPh3)2	 as	 catalyst,	 NEt3	 as	 a	 base	 and	 CuI	 at	 room	 temperature	 gave	 the	 desired	 EE2-BODIPY	
conjugates	in	45-86%	yield	(after	purification	by	silica	gel	column	chromatography).	ER-mediated	uptake	
of	 the	 basic	 EE2-BODIPY	 conjugate	 by	 the	 nuclei	 of	 ER-positive	 MC7-L1	 cells	 was	 confirmed	 by	
fluorescence	imaging.	Discussion	&	Conclusion:	The	synthesis	of	a	series	of	EE2-BODIPY	conjugates	was	
achieved	 via	 Sonogashira	 cross-coupling	 in	moderate	 to	 very	 good	 isolated	 yields.	 In	 vitro	 cell	 uptake	
results	 warrant	 further	 studies	 to	 evaluate	 the	 potential	 of	 the	 EE2-BODIPY	 conjugates	 for	
fluorescence/PET	 imaging	of	ER-positive	breast	cancer.	Fluor-18	 labelling	of	 the	BODIPY	moiety	of	 the	
conjugates	as	well	as	fluorescence	and	PET	imaging	in	tumor	bearing	mice	have	been	projected.	
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Introduction:	 68Ga-labelled	 PSMA	 inhibitor	 analogues	 are	 one	 the	 most	 important	 class	 of	 new	
radiotracers	under	clinical	observation	and	development	for	the	detection	of	prostate	cancer	lesions	and	
metastases.	 68Ga-	 PSMA-11	 (68Ga-PSMA-HBED-CC)	 has	 already	 attested	 its	 suitability	 in	 the	 clinical	
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kinetic	 inertness	 as	 compared	 to	 89Zr-desferrioxamine	 B	 ([89Zr]DFO).[1]	 Here	 we	 designed	 FSC	
derivatized	chelators	for	89Zr	labeling	which	were	expected	to	on	the	one	hand	improve	the	stability	of	
89Zr-complexes	 by	 saturating	 the	 8	 coordination	 sphere	 of	 89Zr	 and	 on	 the	 other	 hand,	 reduce	 the	
number	of	 functionality	making	 it	 suitable	 for	 the	 conjugation	 to	monoclonal	 antibodies.	Materials	&	
Methods	 FSC(succ)2	 and	 FSC(succ)3	 were	 synthesized	 by	 FSC	 reacting	 with	 succinic	 anhydride,	 and	
FSC(succ)2AA	was	synthesized	by	FSC(succ)2	reacting	with	acetic	anhydride.	The	complexation	properties	
of	FSC(succ)2AA	and		FSC(succ)3	with	Zr4+	were	studied	by	reacting	with	ZrCl4.	For	 in	vitro	evaluation	
partition	 coefficient,	 protein	 binding	 property,	 serum	 stability	 as	 well	 as	 acid	 dissociation	 and	
transchelation	 studies	 of	 89Zr-complexes	 were	 evaluated	 and	 compared	 with	 [89Zr]DFO	 and	 89Zr-
triacetyfusarinine	C	([89Zr]TAFC).	The	in	vivo	properties	of	[89Zr]FSC(succ)3	were	further	compared	with	
[89Zr]TAFC	in	nude	mice.	Results	FSC(succ)2AA	and		FSC(succ)3	were	synthesized	with	satisfying	yield.	
The	 complexation	 with	 ZrCl4	 was	 achieved	 using	 a	 simple	 strategy	 resulting	 in	 high-purity	
[natZr]FSC(succ)2AA	 and	 [natZr]FSC(succ)3	 with	 a	 1:1	 stoichiometry.	 Distribution	 coefficient	 of	 89Zr-
complexes	revealed	improved	hydrophilic	characters	compared	to	[89Zr]TAFC.	All	radioligands	showed	
high	 stability	 in	 PBS	 and	 human	 serum	 and	 low	 protein-bound	 activity	 over	 a	 period	 of	 7	 days.	 Acid	
dissociation	and	transchelation	studies	exhibited	the	different	 in	vitro	stabilities	following	the	order	of	
[89Zr]FSC(succ)3	 >	 [89Zr]TAFC	 >	 [89Zr]FSC(succ)2AA	 >	 [89Zr]DFO.	 Biodistribution	 study	 of	
[89Zr]FSC(succ)3	 exhibited	 a	 slower	 excretion	 compared	 to	 [89Zr]TAFC.	 Conclusion	 [89Zr]FSC(succ)3	
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Introduction:	 We	 modified	 a	 fully	 automated	 method	 for	 [18F]NaF	 synthesis	 by	 re-configuring	 a	
commercial	FDG	synthesis	module	(Single	synthesis	module,	Advanced	Cyclotron	Systems,	Inc.).	Materials	
and	Methods:	The	Lookout	program	was	used	to	sequence	the	steps	for	automated	synthesis	using	excel	
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with	 [11C]CO	 [2]	 in	 the	 presence	 of	 tert-butanol	 or	 trityl-amine	 with	 vinyl-halides	 afforded	 2	 and	 3.	
Michael	addition	reactions	were	performed	with	4	by	adding	the	synthons	to	the	reaction	solution	using	
TBAF	as	a	base	in	DMSO.	Synthon	1	was	distilled	into	the	reaction	mixture.	Synthons	2	and	3	were	purified	
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Introduction:	Brain	penetration	and	 targeting	 is	hard	due	 to	complex	structure	with	different	barriers	
such	as	blood–brain	barrier	(BBB)	with	blood–cerebrospinal	fluid	(CSF)	interface	and	CSF–blood	interface	
(1,	2).	Although	these	tight	and	rigid	barriers	protect	brain,	they	also	prevent	penetration	of	molecules,	
drugs	 and	 radiopharmaceuticals	 for	 diagnosis	 and	 therapy	 of	 many	 neurodegenerative	 diseases.	
Parkinson’s	disease	(PD)	is	assumed	to	be	one	of	the	most	frequently	observed	neurodegenerative	disease	







Methods:	 Theranostic	 liposomes	 were	 formulated	 by	 polyethylene	 glycole	 (PEG)	 coated,	 nanosized,	
either	neutral	or	positively	charged,	99mTc	labeled	for	SPECT	imaging	and	pramipexole	encapsulated	for	
PD	therapy.	Their	characterization	and	 in	vitro	release	kinetics	were	evaluated.	 In	vitro	penetration	of	




Promising	 characterization	 and	 release	 profiles	 were	 obtained	 with	 theranostic	 liposomes	 for	 both	
diagnosis	and	therapy	of	PD.	Both	neutral	and	positively	charged	formulations	found	BBB	permeable	in	
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nuclear	medicine	 imaging	 and	 immunohistochemistry.Material	 and	Methods:	 The	 human	 VEGF-A165	
analogue	 was	 radiolabelled	 with	 99mTc	 using	 succinimidyl-6-hydrazinonicotinate	 hydrochloride	 as	 a	
bifunctional	 chelator.	 In	 vitro	 quality	 controls	 were	 performed	 to	 assess	 its	 retained	 structure	 and	
biological	 activity.	 In	 vivo	 studies	 included	biodistribution	 studies	 and	 tumor	 targeting	experiments	 in	
athymic	 nude	 CD-1	 mice	 bearing	 xenograft	 tumors	 from	 ARO,	 K1	 and	 HT29	 cell	 lines.	
Immunohistochemistry	was	performed	on	excised	tumors	to	evaluate	VEGF	and	VEGF	receptor	(VEGFR)	
expression	 in	 the	 lesion	 and	 endothelial	 cells.Results:	 The	 analogue	 was	 labelled	 with	 high	 labelling	
efficiency	(>95%)	and	high	specific	activity,	with	retained	biological	activity	and	structural	integrity.	Tumor	
targeting	 experiments	 revealed	 a	 focal	 uptake	 of	 radiolabelled	 VEGF165	 in	 tumor	 xenografts	 with	
different	 tumor-to-background	 ratios.	 Immunohistochemical	 analysis	 tumors	 revealed	 an	 inverse	
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obtained	 through	 a	 generator),	 and	 to	 the	 fact	 that	 it	 is	 a	 homologous	 element	 to	 99mTc,	 the	
radioelement	 of	 choice	 in	 nuclear	 medicine.	 Inside	 the	 “Vectorisation	 &	 Radiotherapy”	 Axis	 of	 the	
Canceropole	 Grand	Ouest	 and	 the	 IRON	 Labex,	 our	 teams	 have	 developed	 a	 strong	 expertise	 on	 the	
chemistry	and	targeting	of	rhenium	labelled	radiotracers,	from	bench	to	bedside.	Some	examples	of	what	
we	have	been	developing	are	given	below.	188Re-labelled	Lipiodol:	We	have	developed	a	 stable	and	
efficient	 labelling	 of	 Lipiodol	 with	 188Re	 as	 a	 potential	 treatment	 for	 HCC.	 A	 phase	 1	 clinical	 trial	 is	
currently	 running.	 188Re-labelled	 particles:	 188Re	 has	 been	 used	 to	 label	 micro-	 and	 nanoparticles.	
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kit	 solution	 for	 the	 production	 of	 68Ga	 radiopharmaceuticals	 for	 clinical	 applications.	 Materials	 &	
Methods:	Chemical	precursors	DOTA-NOC,	DOTA-RGDfK	dimer,	DOTA-Ubiquicidin	(29-41),	and	PSMA-11	
were	acquired	from	ABX.	Gallium-68	was	obtained	from	an	ITG	generator	while	labeling	was	performed	



























68Ga-DOTA-NOC	 250	µg/ml	 105°C	 C8	Light	 60±12	
68Ga-DOTA-E-[c(RGDfK)]2	 250		µg/ml	 105°C	 C18	Light	 61±6	
68Ga-DOTA-UBI	 250	µg/ml	 105°C	 C18	Light	 56±10	
68Ga-PSMA	 100	µg/ml	 Room	T	 C18	Light	 70±10	
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Introduction:	 The	 clinical	 demand	 for	 68Ga-labelled	 peptides	 is	 constantly	 rising,	 but	 the	 achievable	
radioactivity	per	batch	is	limited	by	the	inventory	of	the	68Ge/68Ga	generator.		One	possible	approach	to	
raising	the	radioactive	yield	is	to	merge	the	radioactive	contents	of	two	68Ge/68Ga	generators	for	one	
batch	 of	 68Ga-peptide.	 The	 key	 to	 this	method	 can	 found	 in	 frame	with	 the	 cationic	 purification	 (1)	
merging	 two	 generator	 eluates.	 Our	 aim	 was	 to	 establish	 this	 method	 in	 the	 synthesis	 of	 68Ga-
DOTANOC.Material	&	Methods:	 The	experimental	 setup	considered	 two	1.85	GBq	 (50	mCi)	 	 iThemba	
68Ge/68Ga-generators	with	calibration	Feb/15	and	Oct/15	and	a	Scintomics	GRP	synthesis	module.	SC-








were	 performed	 as	 usual.	 Results:	 We	 found	 in	 our	 preliminary	 experiments	 more	 the	 98%	 of	 the	
theoretical	68Ga	radioactivity	after	“double	elution”	adsorbed	on	the	PS-H+	SCX	cartridge.	About	15	%	of	














1.73	GBq	 0.87	GBq	 32	min	 50	%	
Experimental	
Dual	generator	
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solution	 of	 100	 µg/mL	 HEPES	 and	 1	 µg/mL	 gentisinic	 acid	 was	 introduced.	 The	 analysis	method	was	
successful	validated	according	to	ICH	in	a	concentration	range	of	HEPES	from	10	µg/mL	to	200	µg/mL.		
This	assay	of	HEPES	was	applied	effectively	in	the	refinement	of	synthesis	sequence	to	the	68Ga-peptides.	





in	 the	 retention	 time	and	 interfere	with	 the	 signal	 of	HEPES,	which	disables	 the	 interpretation	of	 the	
analyse	results.	Conclusion:	We	have	demonstrated	that	HEPES	impurities	in	68Ga-peptides	can	analyse	
by	HPLC	with	respect	to	the	limit	of	the	European	Pharmacopoeia.	We	validated	this	analysis	method	and	
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substituted	 water	 molecules	 of	 the	 precursor	 fac-[99mTc(H2O)3(CO)3]+	 by	 a	 variety	 of	 functional	
groups.2	 The	 aim	 of	 this	 study	 is	 to	 label	 diethyl	 ester	 (S,S)-ethylenediamine-N,N´-di-2-(3-
cyclohexyl)propionic	acid	(L)	with	99mTc(I)-tricarbonyl	precursor.	The	stability	of	the	formed	complex	and	
its	 in	 vitro	 and	 in	 vivo	 properties	 were	 investigated.Materials	 &	 Methods:	 99mTc(I)-L	 complex	 was	
prepared	 by	 a	 two-step	 procedure	 involving	 the	 preparation	 of	 the	 precursor	 [99mTc(CO)3(H2O)3]+,	










intestine.	The	majority	of	 the	radioactivity	of	99mTc(I)-L	complex	was	eliminated	via	 the	 liver	 into	the	
intestine.	 The	 organ	 distribution	 in	 B16-melanoma-bearing	 mice	 showed	 increase	 in	 uptake	 by	 the	
tumor.Discussion/Conclusion:	 99mTc(I)-L	 complex	 revealed	 high	 radiochemical	 purity	 and	 stability	 in	






Am	 Chem	 Soc.	 120:7987-88.	 2.	 Alberto	 R	 (2005)	 New	 organometallic	 technetium	 complexes	 for	
radiopharmaceuticals	imaging.	Top.	Curr.	Chem.	252:	1-44.	
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radiation	 cannot	 damage	 [1-2].	 	 In	 the	 present	 work	 two	 different	 types	 of	 magnetic	 nanoparticles	
(MNPs),	Fe3O4-Naked	and	polyethylene	glycol	600	diacid	 functionalized	Fe3O4	(Fe3O4-PEG600),	were	
synthetized	 in	order	 to	compare	 their	efficiency	as	 radioactive	vectors.	They	were	90Y-labeled	 for	 the	
potential	 use	 in	 localized	 hyperthermia-radionuclide	 therapy.	 Materials	 &	 Methods:	 MNPs	 were	
synthesized	by	 co-precipitation	of	 ferric	 and	 ferrous	 salts	 in	 a	 basic	 solution	 [3,	 4].	 Radiolabeling	was	
performed	by	mixing	0.5	mL	of	aqueous	Fe3O4-Naked	and	Fe3O4-PEG600	MNPs	suspension	with	37	MBq	
90YCl3	(0.001	mL)	and	incubating	at	room	temperature	on	a	shaker	for	one	hour.	Radiolabeled	particles	




Discussion/Conclusion:	 The	 Fe3O4-PEG	 diacid	 MNPs	 showed	 high	 phase	 purity	 and	 favorable	
physicochemical	 and	magnetic	 characteristics	 for	 in	 vivo	 use.	 The	 obtained	 SPA	 value	 for	 Fe3O4-PEG	
diacid	MNPs	(200	W/g)	indicates	that	these	MNPs	could	be	used	as	heating	agents	for	in	situ	magnetic	
fluid	hyperthermia	protocols.	Besides,	high	labeling	yield	(97%)	and	in	vitro	and	in	vivo	stability	of	90Y-
labeled-PEGylated	magnetite	 nanoparticles	 create	 opportunities	 for	 their	 use	 in	 the	 combined	 radio-
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of	PBS.	Results:	68Ga-DOTA-NOC	 is	 produced	 in	 r	 <20	min	with	81.5±5.2	%	 radiochemical	 yield	 (RCY)	
(decay-corrected-d.c.)	and	68Ga-PSMA-11	 is	produced	 in	13	min	with	97.4±2.5	%	RCY	 (d.c.).	Reported	
process	 times	 include	 generator	 elution	 and	 formulation.	 In	 both	 cases,	 final	 products	 show	 high	
radiochemical	purity	(TLC	>	97	%	and	99	%	respectively).Discussion/Conclusion:	Automated	processes	for	
the	 production	 of	 both	 68Ga-DOTA-NOC	 and	 68Ga-PSMA-11	 have	 been	 successfully	 achieved	 using	 a	
commercial	 synthesizer	and	a	68Ge/68Ga	generator.	 The	 labeling	procedures	are	 straightforward	and	
efficient,	 thanks	 to	 the	 low	 elution	 volume	 and	 high	 purity	 of	 the	 generator	 eluate	 (no	 need	 for	
fractionation	or	post-elution	purification).		
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commercially	 produced	 with	 annual	 output	 >1400	 (1.7	 TBq)	 and	 >340	 patient	 doses	 (1.1	 TBq),	
respectively.	Besides	the	commercial	productions	there	is	also	room	for	an	R&D	program,	e.g.,	currently	
improvement	of	 the	production	of	FCH	 is	examined.	Discussion/Conclusion:	As	a	conclusion,	 the	sites	
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and	 radiochemical	 purity	 of	 the	 complex	 were	 controlled	 by	 HPLC	 in	 both	 cases.	 Stability	 in	 time	 in	
labelling	milieu	was	evaluated	up	to	24	hours	post	labelling,	by	HPLC.	Lipophilicity	was	studied	through	
the	apparent	partition	coefficient	between	n-octanol	and	sodium	phosphate	buffer.		In	vitro	stability	was	
assessed	 incubating	 the	 complex	 with	 human	 plasma	 at	 37ºC,	 by	 protein	 precipitation	 method.	 The	
supernatant	was	analysed	by	HPLC.	




Results:	 99mTc-Tricarbonyl	 and	 the	 anidulafungin	 complex	 were	 obtained	 with	 radiochemical	 purity	
higher	than	95%	in	both	cases.	The	product	was	stable	in	labelling	milieu	for	at	least	24	hours,	and	the	
chromatogram	did	not	show	any	degradation	products	in	that	period.		Partition	coefficient	indicates	the	
complex	has	 good	 lipophilicity	 in	order	 to	 insert	 into	 the	 fungus	membrane	 (Log	P=1.5	±	0.1).	 In	 vivo	
studies	 showed	 that	 the	 complex	 presented	 low	 thyroid	 and	 stomach	 uptake,	 indicating	 no	 “in	 vivo”	
reoxidation.	 Elimination	 paths	 were	 mainly	 hepatobiliar	 (55%)	 and	 urinary	 (25%).	 Discussion	 and	
conclusions	:	In	vitro	studies	show	that	the	complex	has	high	radiochemical	purity,	remarkable	in	milieu	




18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 










Introduction:	There	 is	 a	 continued	 interest	 for	development	of	 radiolabeled	RGD	peptides	as	 integrin	




Materials	 and	Methods:	 cRGDfK	was	 functionalized	with	 N3CH2COOH	 and	N3PEG7COOH	 at	 ε-amino	
group	 of	 lysine.	 The	 two	 azide-modified	 derivatives	 (with	 PEG7and	 without)	 were	 then	 clicked	 with	
propargyl	 glycine	 to	 introduce	a	 tridentate	 chelating	unit	 for	 radiolabeling	with	 [99mTc(CO)3(H2O)3]+	
precursor.	The	radiotracers,	99mTc(CO)3-Pra-Tz-CH2-cRGDfK	and	99mTc(CO)3-Pra-Tz-PEG7-cRGDfK	were	
analyzed	by	HPLC.	Analogous	rhenium	complexes	were	synthesized	for	characterization	of	99mTc(CO)3-
labeled	 radiotracers.	 Biodistribution	 study	 of	 the	 two	 radiotracers	 was	 carried	 out	 in	 C57BL/6	 mice	







Tz-CH2-cRGDfK	 (3.01	±	 0.77	%ID/g).	 Tumor	accumulation	of	both	 the	 radiotracers	 reduced	 to	50-60%	
during	blocking	studies	with	cold	cRGDfK	peptide,	suggesting	receptor-mediated	uptake	of	radiotracers.	
Conclusion:	The	two	neutral	99mTc(CO)3	radiotracers	prepared	exhibited	receptor	mediated	uptake	in	
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hydroxide	 or	 ammonium	 carbonate	 solution	 and	 subsequently	with	 1.5	mL	of	water.	 The	 99mTc	was	
recovered	 in	 5	mL	 of	water.	 The	 eluate	 and	 	 other	 effluents	 activities	 (one	 after	 introduction	 of	Mo	




Under	 these	 conditions,	 more	 than	 86%	 adsorption	 and	 elution	 were	 achieved.	 Most	 99mTc	 losses	
occurred	during	rinsing	the	column	with	water,	even	approaching	10%	of	activity	and	due	to	rinsing	the	
column	with	NaOH	or	(NH4)2CO3	after	sorption	Tc-99m	on	Analig	resin	(up	to	3.5%).	The	activity	retained	
on	 	 the	 column	 was	 around	 1%	 	 for	 solution	 in	 NaOH	 and	 	 about	 3%	 for	 (NH4)2CO3,	 respectively.	
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References:	 Bénard	 F,	 Buckley	 K.	 R,	 Ruth	 T.	 J,	 Zeisler	 S.	 K,	 et.al.	 [2014],	 J	 Nucl	 Med.	 55:1017-1022.	
Wojdowska	W,	Pawlak	D,	Parus	J,	Mikołajczak	R.	[2015],	Nucl	Med	Rev.	18,	2:65-69	
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HPLC	 purification	 of	 the	 radiotracer	 and	 also	 characterized	 by	 higher	 susceptibility	 to	 decomposition.	
Herein,	we	reported	a	fully	automated	synthesis	of	[18F]FECNT	from	the	chlorinated	precursor,	which	was	
earlier	 found	 to	 be	 the	most	 stable	 of	 the	 studied	 halo-	 and	 sulfonyloxy-	 analogues	 [5].	Materials	&	
Methods:	The	commercially	available	SynChrom	[18F]	R&D	synthesis	module	was	readily	configured	for	
the	one-step	synthesis	according	to	conditions	achieved	for	the	fluorination	with	non-radioactive	fluoride	
[5].	 The	 radiolabelling	 process	 involved	 a	 classical	 [18F]fluoride	 nucleophilic	 substitution	 from	 the	
chlorinated	 precursor	 (5mg)	 was	 performed	 at	 110°C	 for	 12	 min.	 Crude	 product	 was	 purified	 using	
preparative	 HPLC	 and	 SPE	 methods.	 Results:	 The	 obtained	 yields	 for	 a	 chlorine-for-[18F]fluorine	













[2013]	 J.	 Radioanal.	 Nucl.	 Chem.,	 298:	 1969-1972;	 [5]	 Pijarowska-Kruszyna	 J,	 et	 al.,	 [2014]	 J	 Labelled	
Compd.	Radiopharm.,	57:	148-157;	
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Gamma	 Scintigraphy	 Studies	 with	 99mTc-	 Amoxicillin	 Sodium	 in	 Bacterially	 Infected	 and	 Sterile	
Inflamed	Rats	
Derya	Ilem-Ozdemir,	Oya	Caglayan-Orumlu,	Makbule	Asikoglu	
Ege	 University,	 Faculty	 of	 Pharmacy,	 Department	 of	 Radiopharmacy,	 Ege	 University,	 Bornova,	 Izmir,	
Turkey.	
	
Introduction:	 The	 in-time	 diagnosis	 of	 bacterial	 infection	 is	 extremely	 significant	 for	 the	 accurate	
treatment.	Nuclear	medicine	scintigraphic	 imaging	 is	an	excellent	non-invasive	method	of	whole-body	
scanning,	 allow	 to	 determinate	 infectious	 foci	 in	 all	 parts	 of	 the	 body,	 based	 on	 pathophysiological	
changes	which	occur	earlier	in	the	infection	process	(1-4).	The	aim	of	this	study	was	to	perform	gamma	
scintigraphy	 studies	 with	 bacterial	 infected	 and	 sterile	 inflamed	 rats	 with	 newly	 developed	
radiopharmaceutical	 99mTc-amoxicillin	 sodium	 (99mTc-AMOX).	 Method:	 E.coli	 suspension	 was	
intramuscularly	injected	into	the	right	thigh	muscle	of	rats	to	create	infection	model.	Turpentine	oil	was	
intramuscularly	injected	into	the	left	thigh	muscle	of	rats	to	create	sterile	inflammation	model.	After	the	
infection	and	sterile	 inflammation	 focus	were	allowed	 to	develop	 for	24	hours	 swelling	appeared	and	
gamma	scintigraphy	studies	were	performed.	99mTc-AMOX	(3.7MBq)	was	intravenously	injected	via	tail	









of	 non-target	 (Table	 1).	 Conclusion:	Based	 on	 the	 in	 vivo	 studies,	 99mTc-AMOX	has	 higher	 uptake	 in	
infected	and	inflamed	thigh	muscle	than	healthy	muscle.	The	data	suggest	that	99mTc-AMOX	remained	
at	 the	 infection	 and	 inflammation	 foci	 during	 the	 whole	 experiments,	 there	 being	 no	 statistically	
significant	differences	in	the	ratios	during	the	studied	period	(p≥0.05).		
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Time After Injection 
(h) 
Infected Thigh Muscle 
(Target/Non-Target) 
Inflamed Thigh Muscle 
(Target/Non-Target) 
0 2,35±0,59 1,94±0,09 
1 4,64±1,51 2,94±1,00 
2 2,46±0,19 2,61±0,70 
3 2,33±0,99 2,41±0,12 
4 3,19±1,26 2,73±1,74 
5 4,79±2,82 3,51±1,21 
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better	 infection	 imaging	 	 which	 will	 accumulate	 efficiently	 to	 inflammatory	 foci,	 clear	 rapidly	 from	
background	 tissue,	 discriminate	 between	 bacterial	 infection	 and	 sterile	 inflammation,	 cost	 low	 and	
prepare	easily	we	 labeled	amoxicillin	sodium	(AMOX)	with	99mTc.	The	aim	of	 this	 study	 is	 to	prepare	
99mTc-AMOX	 in	a	simple	method	with	good	 labeling	efficiency	and	evaluate	the	ready	to	use	cold	kit	
formulation	thus	making	it	available	to	the	other	nuclear	medicine	centers.	The	stability	of	99mTc-AMOX	
in	 human	 serum	was	 identified;	 sterility	 and	 pyrogenicity	 of	 the	 radiopharmaceutical	 was	 estimated.	
Method:	To	 investigate	 the	optimum	radiolabeling	 conditions,	 radiolabeling	was	 tested	with	different	
concentrations	 of	 reducing	 (stannous	 chloride	 and	 stannous	 tartrate)	 and	 antioxidant	 (ascorbic	 acid)	
agent.	Radiochemical	analysis	was	performed	with	Radio	Thin	Layer	Chromatography	(RTLC)	and	Radio	
High	Performance	Liquid	Chromatography	(RHPLC)	studies.	Two	different	freeze	dry	kits	were	formulated	
with	 optimum	 labeling	 conditions	 and	 stability,	 sterility	 and	 pyrogenicity	 of	 the	 kits	were	 performed.	
Results:	 The	 effect	 of	 reducing	 agent	 concentration	 on	 the	 radiochemical	 purity	 was	 evaluated	 and	
optimum	reducing	agent	amount	found	200	µg.	Under	these	conditions	labeling	efficiency	was	around	





incubation	 in	 saline	and	human	serum.	Kits	were	 labeled	with	37MBq,	185MBq	and	370	MBq	99mTc.	









References:	 1.Kaul	 A,	 Hazari	 PP,	 Rawat	 H,	 Singh	 B,	 Kalawat	 TC,	 Sharma	 S,	 Babbar	 AK,	 Mishra	 AK.	




18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 














enable	 11C-methylation	with	 both	 [11C]methyl	 iodide	 and	 [11C]methyl	 triflate	 as	well	 as	 direct	 11C-
carboxylation	with	[11C]CO2.	Additional	magnetic	valves	were	installed	to	bypass	the	[11C]methyl	iodide	
















additional	 GM	 tubes	 are	 also	 shown	 on	 the	 touch	 screen.	 Conclusion:	 Reliable	 and	 robust	 routine	
procedures	for	the	production	of	[11C]methionine,	[11C]PK11195,	 	[11C]metomidate	and	[11C]acetate	
were	developed	using	a	modified	Tracerlab	FXC-Pro	module.		The	synthesis	module	can	be	easily	modified	
and	 re-modified	 for	 production	 of	many	 different	 [11C]radiopharmaceuticals.	References:	 	1.	 Shao	 X,	
Hoareau	R,	Runkle		A	et	al.,	[2011],	J.	Label	Compd.	Radiopharm	54:	819-838	
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2.Life	 Sciences,	 Australian	 Nuclear	 Science	 and	 Technology	 Organisation,	 New	 Illawarra	 Road,Lucas	
Heights	NSW	2234,	Australia	
	
Introduction:	Cu(I)-catalyzed	 1,3-dipolar	 cycloadditions	 is	 widely	 used	 in	 labeling	 azido-functionalized	
peptides	and	small-molecules	with18F-alkynes.	We	report	on	the	microfluidic	(ADVION)	synthesis	of	5-
[18F]fluoro-1-pentyne	(5-[18F]-FP)	and	6-[18F]fluoro-1-hexyne	(6-[18F]-FH)	and	application	in	labeling	an	




distillation	 in	 the	 Concentrator	module,	 	 recovered	 in	 the	 reaction	 solvent	 (600ul)	 and	 uploaded	 in	 a	






PBS	 buffer),	 was	 reacted	 (4h	 at	 RT)	 with	 48nmol	 of	 NHS-activated	 azido-PEG.	 The	 azido-protein	 was	
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Introduction:	 Production	 of	 18F-flumazenil	 from	 2-nitroflumazenil	 under	 GMP	 conditions	 is	 primarily	
performed	with	manipulators	or	custom	built	radiosynthesis	modules	with	fixed	components,	as	the	use	
of	N,N-dimethylformamide	(DMF)	at	160°C	prohibits	the	use	of	commonly	available	disposable	cassettes.	








GE	 TRACERlab	 MXFDG.	 A	 non-radioactive	 test	 run	 was	 performed	 with	 the	 ABX	 FDG	 cassette,	 and	
radiosynthesis	was	carried	out	with	the	cassette	components	replaced	by	chemically	resistance	manifolds	






Radiosynthesis	 was	 carried	 out	 with	 the	 manifolds	 replaced	 by	 chemically	 resistant	 ones,	 and	 18F-
flumazenil	 was	 successfully	 obtained	 in	 4	%	 decay	 corrected	 yield.	Conclusions:	Disposable	 cassettes	
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The	 effect	 of	 the	 eluent	 solutions	 (TBAHCO3,	 Kryptand	 K2.2.2)	 on	 the	 radiochemical	 yields	 of	 18F-
Fluoromethylcholine	
Surendra	Nakka,	Hemantha	Kumara	MC,	and	Al-Qahtani	Mohammed*	





this	 work	 was	 to	 improve	 radiochemical	 yields	 of	 18F-Fluoromethylcholine	 ([18F]FCH)	 with	 high	
reproducibility.	The	used	eluent	solution	plays	an	important	role	in	production	of	[18F]FCH	radiotracers.	
[18F]FCH	 is	 manufactured	 under	 GMP	 conditions	 using	 one	 of	 two	 eluent	 solutions	 namely	
Tetrabutylammonium	Bicarbonate	 (TBAHCO3)	 and	Kryptand	2.2.2.,	 each	 time.	Method:	 [18F]FCH	was	
radiosynthesized	 using	 a	 fully	 automated	 synthesis	 module	 TRACERlab	 MX.	 Hardware	 cassette	 and	
reagents	 kit	 purchased	 from	 ABX.	 .	 [18F]FCH	 is	 synthesized	 by	 18F-Fluoroalkylation	 of	 N-N-
Dimethylaminoethanol	 (DMAE)	 in	 presence	 of	 Dimethyl	 Sulfoxide	 (DMSO)	 using	 18F-
Fluorobromomethane	[18F]FBM	as	an	alkylating	agent.	Results:	[18F]Fluoromethylcholine	radiosynthesis	
assisted	 by	 Kryptand	 2.2.2	 shown	 irregular	 or	 poor	 distillation	 of	 18F-Fluorobromomethane,	which	 is	
observed	 by	 pressure	 trending	window	 on	 TRACERlab	MX	 during	 distillation	 step	 very	 poor	 gas	 flow	
through	the	four	silica	cartridges	been	observed	which	in	turn	leads	to	production	of	very	less	amounts	
of	 	 [18F]FCH.	 Tetrabutylammonium	Bicarbonate	 (TBAHCO3)	 assisted	18F-FCH	 radiosynthesis	 observed	
with	regular	and	continuous	distillation	of	18F-Fluorobromomethane	through	the	four	silica	cartridges.	
[18F]FCH	 solution	 proved	 high	 radiochemical	 purities	 (>99%),	 Residual	 solvents	 analyzed	 using	 Gas	
Chromatography	 (GC),	 DBM	 &	 DMAE	 is	 not	 identified.	 Conclusion:	 Choice	 of	 Tetrabutylammonium	
Bicarbonate	 (TBAHCO3)	 as	 eluent	 solution	 shown	 very	 consistent	 and	 improved	 radiochemical	 yields	
decay	corrected	20-25%	over	Kryptand	2.2.2	as	eluent	solution.	
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N	Mambilima,	 SM	Rubow,	University	 Teaching	Hospital,	 Lusaka,	 Zambia,	 and	 Stellenbosch	University,	
South	Africa	
	
Introduction:	Pharmacopoeial	 or	manufacturer’s	 radiochemical	 purity	 (RCP)	 analysis	methods	 are	 not	
always	practical	in	a	hospital	setting,	leading	to	modifications	or	substitution	with	quicker,	simplified,	or	
























18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 
























with	 a	 solution	 50:50	 acetate	 buffer:acetonitrile	 (pH=3,6)	 and	 automatically	 injected	 onto	 a	





GBq/μmol.	 Radiochemical	 purity	 exceeded	 98%.	 Conclusions:	 A	 fast	 and	 reliable	 procedure	 for	 the	
production	 of	 [18F]FEPPA	 was	 successfully	 implemented,	 drastically	 reducing	 the	 total	 time	 of	 the	
radiosynthesis	compared	to	the	previous	published	method	(17	min	compared	to	36	min)	[3].	References:	
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lower	excretion	via	 the	urinary	pathway:	33.2%ID	at	10	min	and	62.2%ID	at	60	min	p.i,,	 compared	 to	
44.1%ID	at	10	min	and	77.9%ID	at	60	min.	p.i.,	respectively.	
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Discussion/Conclusion:	 RESCA1-TATE	 easily	 forms	 a	 chemically	 and	 biologically	 stable	 complex	 with	
{Al18F}2+.	 The	 radiotracer,	 however,	 showed	 lower	 uptake	 in	 organs	 known	 for	 high	 somatostatine	
expression	 in	 comparison	 with	 the	 clinical	 standard.	 This	 could	 be	 caused	 either	 by	 in	 vivo	 binding	
competition	 with	 non-labelled	 RESCA1	 conjugate,	 accelerated	 clearance	 or	 lower	 binding	 affinity	 of	
[Al18F]2.	Future	experiments	with	HPLC	purified	radiotracer	in	competition	binding	studies	in	vitro	and	in	
vivo,	 and	 investigation	 in	 a	 high	 somatostatin	 receptor	 expressing	 tumour	mouse	model	will	 have	 to	
clarify,	whether	 specific	activity,	 receptor	affinity	and/or	 in	vivo	kinetics	of	 [Al18F]2	can	explain	 these	
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processed	 to	 form	 nanoparticles.	 Due	 to	 its	 amphiphilic	 character,	 mucoadhesive	 properties	 and	 a	
relatively	 high	 resistance	 to	 the	 effect	 of	 digestive	 enzymes,	 the	 resulting	 nanocarriers	 offer	 great	
potential	for	oral	drug	delivery	purposes	.The	aim	is	optimization	of	99mTc	radiolabelling	of	different	kind	
of	zein	nanoparticles	(ZNP)	and	the	study	by	molecular	imaging	of	their	biodistribution	in	Wistar	rats	after	
oral	 gavage.	 The	 evaluated	 nanoparticles	 were	 bare	 zein	 nanoparticles	 (ZPN)	 and	 decorated	 with	 3	
different	 slippery	 polymers	 (ZNP-A,	 ZNP-B	 and	 ZNP-C).	Materials	 &	Methods:	All	 nanoparticles	 were	





8h	 post-administration.	 SPECT	 acquisition	 protocol	 was	 set	 to	 account	 for	 radionuclide	 decay.	 For	
quantitative	 analysis	 data	 sets	were	 exported	 to	 PMOD	 software	 and	VOIs	 drawn	over	 CT	 images	 on	
stomach	and	 intestine,	count	 ratios	calculated	 in	 respect	 to	 total	animal	counts	and	maximum	counts	
normalized	to	the	last	image	(8h)	for	each	nanoparticle	type.	Results:	Radiochemical	purity	was	>95%	for	
ZNP-A	and	NPZ	using	[SnCl2]=0.5	mg/mL,	while	1.0	mg/mL	was	needed	for	ZNP-B	and	ZNP-C	to	get	similar	
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1.7.	Discussion/Conclusion:	The	preparation	of	68Ga-DOTANOC	 is	 a	 very	 robust	process	 giving	a	high	
quality	product	in	a	very	reliable	manner.	In	spite	of	high	68Ge	content	in	the	68Ga	elution	with	the	iTG	
generator,	the	product	has	negligible	68Ge	content.	The	product	has	very	low	levels	of	68Ga	colloids	and	
negligible	amounts	of	 free	68Ga	and	gives	a	 very	 clean	HPLC	 trace.	We	conclude	 that	 this	method	of	
production	gives	a	safe,	high	quality	product.	
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being	 considered	 a	 promising	 treatment	 of	 musculoeskeletal	 injuries,	 however,	 their	 trafficking	 and	








sedation.	 No	 immunosuppressive	 agents	 were	 administered.	 Results:	 Early	 immune	 response	 to	
xenogenic	 MSCs-ah	 was	 not	 detected	 during	 the	 study.	 Neither	 adverse	 reaction	 nor	 technical	










18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 























Materials	 &	methods:	We	 have	 investigated	 several	 conditions	 and	 solvents	 for	 synthesizing	 [18F]F-
exendin-4.	Alkyne	tosylate	and	a	[18F]fluoride-Kryptofix	complex	were	allowed	to	react	 in	DMSO	for	5	





for	 radiochemical	 analysis	 and	 SA	 determination	 of	 the	 [18F]FP	 and	 [18F]F-exendin-4.	 Results:	 18F-
labelling	of	 [18F]FP	proceeded	 in	 an	 50%	 radiochemical	 yield	 (RCY).	 Isolation	of	 [18F]FP	by	HPLC	was	
efficient	and	the	radiochemical	purity	was	>	99%.	The	RCY	of	[18F]F-exendin-4	ranged	between	25-60%	
(calculated	from	[18F]FP,	uncorrected)	and	the	radiochemical	purity	was	>	96%.	The	SA	was	up	to	350	





18th European Symposium  
on Radiopharmacy and Radiopharmaceuticals 


















biodistribution	 studies	 and	 an	 experimental	 radionuclide	 therapy	 in	 a	 CCK2R-specific	 mouse	 tumour	
model	 using	 two	 177Lu-labelled	 cyclic	 minigastrin-analogues:	 DOTA-cyclo[γ-D-Glu-Ala-Tyr-D-Lys]-Trp-
Met-Asp-Phe-NH2	 (DOTA-cyclo-MG1)	 and	 DOTA-cyclo[γ-D-Glu-Ala-Tyr-D-Lys]-Trp-Nle-Asp-Phe-NH2	
(DOTA-cyclo-MG2).	Based	on	results	of	biodistribution	studies	dosimetric	considerations	for	humans	were	

















group,	 respectively.	 For	 the	 A431-mock-tumours	 lower	 factors	 of	 1.2	 and	 1.7	were	 observed	 in	 both	
treatment	groups	proving	a	receptor-specific	effect.	On	the	basis	of	dosimetric	extrapolation	to	humans	
first	therapeutic	applications	in	patients	should	start	with	4	repeated	administrations	of	3-5	GBq	to	limit	
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synthesis	 of	 radiopharmaceuticals	 used	 for	 cell	 labelling.	 Due	 to	 its	 half	 life	 (78,4h)	 89Zr	 labelled	
radiopharmaceuticals,	 could	 possibly	 enable	 long-term	 “in	 vivo”	 cell	 tracking	 with	 several	 attractive	
















dependent	 (0.3-1.5ml).	 	 Yield	 of	 89Zr-tropolone	 solution	was	 above	 85%	with	 pH	 between	 7-7.5	 and	
extraction	into	octanol	above	94%.	Yield	of	89Zr-oxine	solution	(50%EtOH)	was	between	25-71%	with	pH	
between	 7-9	 and	 extraction	 into	 octanol	 above	 86%.	 Conclusion:	 Concentration	 of	 coordinating	
radiometals	111In,	68Ga	and	89Zr	on	an	anion	exchange	column	in	HEPES	allows	on-column	formation	of	
tracers	(oxine,	tropolone)	 in	very	small	volumes	suitable	for	cell	 labelling	with	good	yields	and	quality.	
This	 is	 a	 versatile	 and	 promising	 tool	 to	 prepare	 tracers	 on	 automated	 systems	 further	 used	 for	 cell	
labelling	and	potentially	suitable	for	clinical	practice.	
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small	 peptides	 as	 radiopharmaceuticals	 thanks	 to	 the	 use	 of	 a	 chelating	 agent	 with	 several	 clinical	
applications.	Numerous	gallium-68	labelled	peptides	(eg.	[68Ga]DOTA-TOC/-NOC,	[68Ga]HBED-PSMA-11,	
[68Ga]NODAGA-RGD)	have	shown	their	interest	[1,2].	Developing	an	easy,	rapid	and	performant	labelling	
method	 is	 important.	 Different	 methods	 for	 the	 pre-purification	 of	 the	 generator	 eluate	 have	 been	
explored	 in	 the	 literature,	 although	 recent	 improvement	 on	 some	 generator	 brands	 (i.e.	 low	 68Ge	
breakthrough	 and	 low	 metallic	 impurities	 content),	 makes	 this	 pre-purification	 unnecessary.		





without	 pre-purification	 in	mAIO	module.	 Optimal	 experimental	 conditions	 (concentration	 of	 sodium	
acetate,	quantity	of	precursor,	temperature	and	duration)	were	determined	for	each	peptide.	Labelling	
efficiency	was	determined	on	Waters	HPLC	system.	Results:	DOTANOC,	DOTATOC,	HBED-PSMA-11	and	
NODAGA-RGD	 were	 tested	 for	 68Ga-labelling	 without	 pre-purification.	 Optimal	 and	 reproducible	
conditions	were	found	for	each	peptide.	68Ga-peptides	were	synthesised	with	excellent	 incorporation	
yields,	 (90-99%)	 and	 good	 synthesis	 yields	 >	 60%	 in	 less	 than	 15	 min.	 Discussion/Conclusion:	 We	
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more	 efficient	 use	 of	 68Ge/68Ga	 radionuclide	 generators,	 despite	 the	 limitations	 in	 the	 variety	 of	
generator	 eluent’s	 composition	 and	 pH.	 	 Our	 aim	 was	 to	 develop	 a	 dry	 kit	 formulation	 	 for	 68Ga	




4mL	0.1M	HCl).	 For	 quality	 control	 of	 the	 68Ga–PSMA-11	 the	RP-RadioHPLC	 (Kinetex	 C18	 150mm;	A:	
0.1%TFA/H2O,	 B:	 0.1%TFA/CAN)	 was	 used	 with	 gradient	 conditions	 (according	 to	 M.	 Eder	 et	 al.	
Pharmaceuticals	2014,	7,	779-796)	as	well	as	in	isocratic	elution	(optimally	set	to	17%	B)	which	visualized	






ascorbic	 acid.	 The	 yield	 of	 68Ga	 labelling	 of	 PSMA-11	 from	 the	 freeze-dried	 kit	 	 was	 >	 95%.	 	 The	
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have	a	disproportionately	high	 radiobiological	 effect.	 This	 is	 seen	as	 the	effect	of	 the	multiplicity	 and	
predominance	of	very	 low	energy	electrons	 in	dose	delivery.	Despite	many	years	of	research	 in	Auger	
emitters,	only	few	direct	measurements	of	the	radiobiological	effect	of	such	Auger	cascades	have	been	
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Introduction:	 The	αvβ3	 integrin	 receptors,	 expressed	 on	 tumor	 cell	membranes	 can	 be	 preferentially	
targeted	 by	 peptides	 containing	 the	 RGD	 sequence.	 NOTA-SCN-Bn-E-[c(RGDyK)2],	 NODAGA-RGDfK,	
DOTA-E-[c(RGDfK)2],	and	DOTA-RGDfK	were	labelled	with	Ga-68	and	tested	for	radiolabelling	yield,	purity,	
stability,	 in	 vitro	 binding,	 ex	 vivo	 biodistribution,	 and	 in	 vivo	 imaging.	Materials	 and	 Methods:	 The	
radiolabelling	was	performed	using	an	automated	system	with	inline	quality	control.	Fraction	of	68GaCl3	
eluate	 from	an	organic	matrix	 based	 68Ge/68Ga	 generator,	 400-700	MBq	 in	 2	mL,	was	 used	 to	 label	
















[c(RGDfK)2]	 makes	 it	 our	 option	 for	 further	 investigations	 as	 therapeutic	 agent.	 	 Research	 contracts	
CRP16500	IAEA	and	MEN	UEFISCDI,	PN	II	228/2014	are	acknowledged	for	financial	support.		
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68Ga-RM2	 for	 further	 clinical	 research,	 robust	 methods	 for	 preparation	 of	 this	 promising	 tracer	 are	
needed.	Herein	we	describe	the	results	of	automated	synthesizer	based	68Ga-radiolabelings	of	RM2	as	
well	as	of	simplified	“shake-and-bake”	kit-preparations.	Materials	and	Methods:	The	automated	68Ga-
radiolabeling	 was	 optimized	 on	 a	 PharmTracer	 module	 (Eckert&Ziegler).	 The	 influence	 of	 several	
scavengers	was	 investigated,	as	well	 as	a	processes	with	and	without	 subsequent	purification	via	C18	
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[18F]fluoro-exendin-4	 is	depicted	 in	Scheme	1.	The	dried	 [18F]fluoride-Kryptofix	 complex	was	 reacted	
with	tosylated	prosthetic	compound	1	in	dimethylsulfoxide	at	80	°C.	After	chromatographic	isolation,	the	
18F-labelled	azide	2	was	allowed	to	react	with	cyclooctyne-derivatised	exendin-4	in	ethanol/water	at	60	
°C	 for	30	min.	 Isolation	and	radiochemical	analysis	of	 [18F]fluoro-exendin-4	was	performed	using	high	
performance	 liquid	 chromatography	 (HPLC)	 with	 radiodetector.	 Results:	 Preliminary	 results	 showed	
efficient	reaction	between	prosthetic	reagent	[18F]2	and	exendin-4	precursor	with	a	radiochemical	yield	
of	30	%.	The	absence	of	major	radioactive	by-products	assured	neat	purification	using	HPLC.	The	average	
isolated	 yield	 of	 [18F]exendin-4	 after	 HPLC	 purification	was	 180	MBq	 starting	 from	 3.5	GBq	 aqueous	
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Introduction:	 Automated	 processing	 modules	 for	 target	 processing	 and	 production	 of	
radiopharmaceuticals	 become	 to	 be	 a	 more	 and	 more	 required	 in	 both	 R&D	 and	 routine	 practice.	
However,	it	turns	out	that	available	systems	for	processing	of	targets	for	radiometal	production	and	for	
labeling	 performed	 via	 microfluidic	 approach	 are	 still	 rather	 limited.	 Our	 aim	 was	 to	 develop	 a	
multipurpose	automated	system	for	processing	solid	state	 targets	and	a	microfluidic	 system	based	on	
PMMA	chip.		Materials	&	Methods:	Stingray	–	Automated	
microfluidic	 system.	 The	 device	 is	 versatile	 automated	
system	 that	allows	 for	 control	of	wide	 range	of	processes	
performed	 on	 a	 microfluidic	 chip.	 The	 system	 makes	
possible	 operations	 like	 precise	 mixing,	 separation,	
extraction	 or	 nanoparticle	 formation	 in	 small-scale.	 The	
system	 consists	 of	 3	 independent	 inlets	 for	 3	 different	





for	 a	 repeated	 return	 of	 a	 sample	 to	 the	microfluidic	
chip	what	may	enhance	dramatically	the	yield.	CRAB	–	
versatile	 platform	 for	 separation,	 formulation	 and	
simple	labelling	processes		The	main	parts	of	the	system	
are	 two	 reactors,	 two	 selectors,	 peristaltic	 pump,	 3/2	
way	valves,	and	the	column.	Prime	reactor	R1	allows	for	
transport	solid	target	material	from	shielding	container	




positions	 are	 available	 for	 uploading	 the	 solvents	 into	
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Introduction:	 Formulations	 of	 cyclotron-produced	 99mTc	 contain	 trace	 amounts	 of	 other	 Tc	 isotopes	
depending	on	the	isotopic	composition	of	starting	100Mo.	Presence	of	other	nuclides	may	affect	image	






was	 measured	 using	 gamma-ray	 spectrometry.	 Percentage	 of	 each	 radioactive	 contaminant	 was	
calculated	dividing	activity	of	each	isotope	by	total	activity	in	the	sample.	Method	2,	“Shielding”:	A	vial	
containing	formulated	99mTc	was	measured	in	a	calibrated	ionization	chamber.	Then,	it	was	inserted	into	
a	 6	 mm	 thick	 lead	 canister,	 used	 in	 nuclear	 medicine	 for	 99Mo	 breakthrough	 determination,	 and	
measured	using	gamma-ray	spectrometry.	The	activity	of	each	radioactive	contaminant	was	calculated	




produced	 99mTc	 with	 “dilution”	 method	 (99.983±0.007%)	 compared	 to	 “shielding”	 method	
(99.979±0.009%).	Since	both	methods	require	measurements	by	gamma-ray	spectrometry,	they	are	time-
consuming,	involve	elaborate	calculations,	and	demand	specific	expertise.	“High-energy	breakthrough”	
measurements	 showed	 good	 correlation	with	 the	 results	 of	 gamma-spectrometry.	Conclusions:	With	
“shielding”	method,	 lead	canister	attenuated	low-energy	gamma-emission	(including	from	99mTc)	and	
allowed	 detecting	 impurities	 present	 in	 trace	 amounts	 with	 better	 sensitivity.	 While	 “high-energy	
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The	 composition	 of	 each	 tissue	 type	 is	 given	 in	 ICRP	 reports	 70	 and	 89	 and	 ICRU	 46	 [4-5].	 Results:	
Calculated	results	are	given	for	imparted	energy	per	transformation	dose	equivalent	and	effective	doses	
for	 different	 organs.	 The	 effective	 doses	 were	 between	 9,17nSv	 for	 bone	 surface	 to	 122.4	 mSv	 for	
stomach.	As	the	total	dose	is	estimated	to	be	126.73	mSv	it	is	obvious	that	the	highest	part	is	received	by	











12625-M	 report,	 Los	Alamos,	NM:	 Los	Alamos	National	 Laboratory.	 4.	 Zubal	 IG,	Harrell	 CR,	 Smith	 EO,	
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Chemical	 analysis	of	 the	 rituximab	 radioimmunoconjugates	 in	 lyophilized	 formulations	 intended	 for	
oncological	applications	
Darinka	 Gjorgieva	 Ackova1,	 Katarina	 Smilkov1,	 Petre	 Makreski2,	 Trajče	 Stafilov2,	 Emilija	 Janevik-
Ivanovska1	
1Department	of	Pharmacy,	Faculty	of	Medical	Sciences,	University	Goce	Delčev	–	Štip,	R.	Macedonia	
2Department	 of	 Chemistry,	 Faculty	 of	 Natural	 Sciences	 and	 Mathematics,	 University	 “Ss.	 Cyril	 and	
Methodius”-	Skopje,	R.	Macedonia	
	
Introduction:	 Therapeutic	 and	 diagnostic	 antibodies	 have	 become	 the	 fastest	 growing	 class	 of	
biopharmaceutical	drugs	with	more	than	100	antibodies	in	different	phases	of	clinical	trials	today.	For	the	





(FTIR)	 spectroscopy	 and	 Raman	 spectroscopy	 are	 one	 of	 the	 biophysical	 methods	 for	 structural	
characterization	of	proteins	because	of	their	sensitivity	to	the	composition	and	architecture	of	molecules.	
Here	 we	 used	 vibrational	 spectroscopy	 to	 characterize	 the	 physico-chemical	 stability	 and	 structural	
changes	 of	 three	 immunoconjugates	 of	 rituximab,	 intended	 for	 labeling	 with	 radioisotope	 of	 choice	
(177Lu,	 90Y	 and/or	 68Ga),	 relevant	 for	 the	 stability	 of	 therapeutic/diagnostic	 antibodies	 during	
preparation,	 storage	 and/or	 transport.	 Materials	 and	 Methods:	 Rituximab,	 conjugated	 with	 three	
different	 bifunctional	 chelating	 agents	 (BFCAs),	 p-SCN-Bn-DOTA,	 p-SCN-Bn-DTPA	 and	 1B4M-DTPA	 in	 a	
form	of	lyophilized	preparations	non-radioactive	labeled	with	above	mentioned	radioisotope	analogues,	
was	 subjected	 to	 characterization	 and	 determination	 of	 secondary	 structure	 and	 quality	 parameters	
(purity,	 integrity,	 fragmentation	 and	 aggregation	 of	 the	 antibody)	 by	 FT-IR	 and	 Raman	
spectroscopy.Results:	 Based	 on	 the	 frequencies	 assigned	 for	 amide	 I,	 II	 and	 III	 bands,	 the	 studied	
formulations	 contain	 highest	 percentage	 of	 β-sheet	 conformation	 (antiparallel	 and	 parallel)	 in	 the	
structure,	 followed	by	α-helices.	 Significant	 changes	upon	processes	 of	 conjugation	 and	 lyophilization	
were	not	observed	in	comparison	with	spectra	of	native	antibody	(Fig.1).	Vibrational	spectroscopic	data	
allow	 detection	 of	 alterations	 in	 investigated	 protein	 models	 as	 well	 as	 rapid	 assessment	 of	
conformational	 changes	 resulting	 from	 ligand	 binding,	 aggregation	 or	 macromolecular	 interactions.	
Appearance	of	 strong	 absorption	bands	below	1620	 cm–1	 can	be	 correlated	with	 aggregation-usually	
associated	with	the	formation	of	new	strong	β-sheet	structures.	According	to	the	obtained	spectra,	it	is	
important	that	we	observed	retaining	of	native	structure	of	the	antibody	and	no	obvious	aggregation	(the	
lowest	 band	 frequency	 detected	 was	 1620	 cm–1	 with	 weak	 intensity)	 in	 all	 samples	 of	 lyophilizated	
conjugates.	
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Introduction:	 The	 development	 of	 radiolabeled	 small	 peptide	 or	 peptidomimetic	 ligands	 can	 bind	
platelets	and	their	specific	expressed	receptor	have	been	suggested	as	a	new	approach	to	detect	the	clot	
location	and,	more	essentially,	to	determine	the	age	and	morphology	of	the	evolving	thrombus.	This	new	
approach	 is	 focused	 on	 the	 use	 of	 a	 series	 of	 radiolabeled	 platelet	 GPIIb/IIIa	 receptor	 antagonists.	
Tirofiban	N-(butylsulfonyl)-	4-O-(4-(4-piperidyl)-L-tyrosine	is	a	non-peptide	tyrosine	derivate.		The	aim	of	
the	study	was	to	introduce	radioactive-labeled	tirofiban	as	a	specific	imaging	agent	for	acute	DVT	and	to	
determine	 the	 serum	 concentrations	 in	 normotensive	male	Wister	 rats	with	 and	without	 deep	 acute	
venous	 thrombosis	 in	 order	 to	 confirm	 the	 animal	model	 of	 acute	 venous	 thrombosis.	Material	 and	
Methods:	Venous	thrombosis	was	induced	by	ligature	of	the	femoral	vein	in	rats	whose	blood	was	made	
hypercoagulable	by	 intravenous	administration	of	 tissue	 thrombin.	 	 The	determination	of	 Tirofiban	 in	
serum	 was	 performed	 using	 validated	 HPL	 method	 with	 UV	 detection.	 Results:	 The	 labeling	 was	




determination	 of	 the	 serum	 concentration	 planar	 imaging	 was	 performed	 at	 30	 and	 60	 min	 after	
application.	Sensitivity	and	specificity	were	determined	using	the	ratio	of	‘left	leg	positive	for	DVT’	to	‘right	
leg	negative	for	DVT’.	The	obtained	ratio	was	1.54	after	30	min	and	5.04	after	60	min.		These	values	were	
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documented,	 as	 well	 human	 resources,	 education,	 suitable	 training	 and	 local	 demand	 for	 the	
Radiopharmacy	and	Nuclear	Medicine	services.		The	Radiopharmacy	Practice	requires	well-defined	and	
controlled	conditions	to	avoid	the	risk	contamination	with	microbes,	pyrogens	and	particulate	matter	as	







also	 infectious	diseases.	 	 In	 light	of	the	foregoing,	therefore,	radiopharmacy	has	a	huge	role	to	play	 in	
responding	 to	 the	 unfolding	 new	 disease	 trends	 in	 sub-Saharan	 Africa.	 The	 preparation	 of	
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The	 substantial	 confusion	 and	 challenge	 in	 the	 same	 time	 is	 to	 define	 the	 appropriate	 and	 sufficient	
knowledge,	understanding	and	competences	corresponding	to	position	of	professionals	 in	the	working	
place,	 including	 the	 type	 and	 level	 of	 formal	 education.	Methods:	 The	 goal	 of	 the	 Academic	Master	
program	for	Radiopharmacy	in	English,	with	the	recognized	accreditation	from	the	National	Body	in	2014	
and	 recommended	by	 the	Ministry	of	Education	and	Science	 in	our	 country	according	 to	 the	Bologna	
system	 with	 120	 ECTS	 credits	 is	 to	 give	 the	 opportunity	 for	 all	 students	 with	 finished	 academic	








three	 categories:	1.	 Specific	 knowledge	and	 skills:Design	of	Radiopharmacy	 facilities	and	QA	program,	
Production	 and	 synthesis	 of	 radionuclides	 and	 radiopharmaceuticals,	 Quality	 control	 of	
radiopharmaceuticals	 2.	 Basic	 knowledge	 and	 skills:	 Leadership	 and	 collaboration,	 Communication,	
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Introduction:	 The	 RGD-recognising	 αVβ3,	 αVβ5	 and	 α5β1	 integrins	 are	 known	 to	 be	 involved	 in	
carcinogenesis	and	are	overexpressed	in	many	types	of	tumours	compared	to	healthy	tissues;	thereby	
they	 have	 been	 selected	 as	 promising	 therapeutic	 targets.	 Positron	 emission	 tomography	 (PET)	 is	
providing	a	unique	non-invasive	screening	assay	to	discriminate	which	patient	is	more	prone	to	benefit	
from	 antiangiogenic	 therapies,	 and	 extensive	 research	 has	 been	 carried	 out	 to	 develop	 a	 clinical	




of	 its	 preclinical	 biologic	 properties.	 Materials	 &	 Methods:	 A	 novel	 bifunctional	 synthon	
([18F]FPyPEGCBT)	has	been	developed	to	accommodate:	i)	an	efficient	[18F]F-	incorporation	and	ii)	a	mild	
conjugation	to	biomolecules.	Then,	[18F]FPyPEGCBT	has	been	conjugated	to	a	cyclic	RGD	peptide	known	
for	 its	 high	 binding	 affinity	 and	 selectivity	 for	 integrin	 αVβ3.	 The	 in	 vitro	 binding	 characteristics	 of	
FPyPEGCBT-c(RGDfK)	were	analysed	by	standard	binding	assay	 in	U-87	MG	and	SKOV-3	cancer	models	
and	 its	 selectivity	 towards	 integrins	 by	 siRNA	 depletions.	 Its	 preclinical	 potential	was	 studied	 in	mice	
bearing	 subcutaneous	 tumours	 by	 ex	 vivo	 biodistribution	 studies	 and	 in	 vivo	 microPET/CT	 imaging.	
Results:	[18F]FPyPEGCBT	was	prepared	from	its	corresponding	2-trimethylammonium	triflate	precursor	
and	purified	by	solid-phase	extraction.	Ligation	of	[18F]FPyPEGCBT	to	the	cysteine-modified	cyclo-(RGDfK)	
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